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The p73 gene was first discovered in 1997 as a family member of p53, and since then this gene 
has been studied extensively in cancer biology. Among its two main classes of isoforms, 
TAp73 acts as a tumor suppressor, while in contrast ΔNp73 was shown to act in a dominant 
negative fashion as an oncogene which opposes the functions of TAp73 and p53. This thesis 
focuses on further deciphering the role of p73 isoforms in tumor angiogenesis, tumor 
microenvironment and drug resistance which promote tumor development. Tumor initiation 
heavily relies on the loss of tumor suppressors or gain of function of oncogenes in tumor cells, 
subsequently resulting in the production of factors that modulate the tumor microenvironment 
in favor of tumor progression. Solid tumors commonly have a hypoxic core due to extensive 
growth in size, thus limiting oxygen levels for tumor cell survival. Tumor cells overcome this 
via producing angiogenic factors to recruit more blood vessels into the tumor for meeting the 
oxygen and nutrition demands. In Paper I, we discovered that absence of the tumor suppressor 
TAp73 leads to increased production of angiogenic factors and tumor angiogenesis. Moreover, 
this angiogenic response was driven via HIF1α. On the other hand, ΔNp73 showed positive 
regulation of angiogenic gene expression and angiogenic events. In Paper II, we further 
verified the role of TAp73 in regulation of the angiogenic chemokine CCL2, where TAp73 
suppresses CCL2 expression via regulation of NFκB activity. Additionally, TAp73 deficient 
tumors favored increased recruitment of tumor supporting macrophages. A negative correlation 
of TP73 with macrophage markers was also confirmed in several human cancer datasets. In 
Paper III, we further investigated the role of ΔNp73-mediated regulation of HIF1α stability in 
normoxia. ΔNp73 was found to positively regulate HIF1α stability via regulation of ECV 
genes, which are important components of the proteasome mediated HIF1α degradation 
pathway. Finally, in Paper IV, we addressed ΔNp73’s involvement in drug resistance. 
Oncogenic ΔNp73 upregulated the expression of multidrug resistance related ABC 
transporters. Additionally, ΔNp73 deficiency reduced drug efflux capacity of breast cancer 
cells. The positive correlation of ABC transporters and ΔNp73 was also confirmed in 
melanoma.  
In summary, the findings in this thesis further enlighten the role of p73 isoforms in different 
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1 INTRODUCTION 
1.1 CANCER AND TUMOR 
Tumor is a generic term given for a mass or lump of cells. In normal physiology, cell division 
is a regular and tightly controlled event, however, under unfavorable circumstances when cells 
undergo abnormal cell division it leads to the formation of tumors or neoplasms. Tumors can 
be benign or malignant. Benign tumors are usually confined to a specific location and cannot 
invade neighboring tissue or spread to other parts of the body. Malignant tumors not only 
invade but also acquire the ability to migrate to distant sites through the circulatory or lymphatic 
system, resulting in cancer. According to WHO, cancer was the second major cause of global 
death claiming nearly 8.8 million lives worldwide in 2015. In males, the most common types 
of cancers include lung, prostate, colorectal, gastric and liver cancer whereas in females it 
includes breast, colorectal, lung, cervix and gastric cancer1. The term cancer was first coined 
from the Greek word ´´karkinos´´ for crab because similar to a crab ‘once it gets hold of you it 
never lets go’2. The reason behind the use of this terminology is that even after a cancer patient 
is treated with currently available therapies, there may still be dormant or resistant cells that 
later undergo clonal expansion to form new tumors. This still holds cancer as an unresolved 
mystery.  
 
Figure 1. The hallmarks of cancer. Adapted from Hanahan and Weinberg, Cell 2011 in 
compliance with the conditions of the Elsevier user license. 
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1.1.1 The hallmarks of cancer 
Hanahan and Weinberg primarily listed six important traits that normal cells need to acquire 
starting from the initiation of cancer to cancer development, progression and metastatic 
dissemination3. In an updated version, they included four new features that are referred to as 
the emerging hallmarks of cancer4. Together, these ten prime characteristics are: (1) continuous 
proliferative signaling causing uncontrolled clonal expansion (2) insensitivity to growth 
inhibitory signals (3) resistance to cellular apoptosis or cell death (4) limitless clonal expansion 
(5) tumor angiogenesis (6) invasion and metastasis to secondary site in distal part of the body 
(7) altered cell metabolism (8) recurrent mutation and genomic instability (9) altered 
phenotypic characteristics to avoid immune cell mediated clearance and (10) sustained 
inflammatory microenvironment4. All these features have been depicted in Figure 1.   
1.1.2 Oncogenes and tumor suppressors 
Tumor cells are very distinct from their normal cellular counterparts in many aspects including; 
growth regulation, morphology, cellular interaction, membrane proteins, and differential gene 
and protein expression. These unique features are mainly supported by two family of genes, 
namely proto-oncogenes and tumor suppressor genes, which function to control cell growth, 
survival and differentiation; nonfunctional mutation or deletion of tumor suppressor genes may 
result in cancer progression5. In most cases, cancer results due to gain of function of proto-
oncogenes/oncogenes and/or loss of function of tumor suppressor genes and proteins. 
Proto-oncogenes are a class of genes, which play a significant role in different checkpoints of 
cell division, differentiation, proliferation, cell survival and cell death (apoptosis); over-
activation of these genes results in malignancy. Proto-oncogenes mostly remain active during 
embryonic development and are generally turned off during adulthood. Mutations or genetic 
alterations in the DNA, like deletions or amplifications, may activate proto-oncogenes. This 
could ultimately increase expression or alter proto-oncogene function to provide survival 
advantage to non-tumoral cells. The most common proto-oncogenes are growth factors, 
receptor/non-receptor tyrosine kinases, serine threonine kinases, G-protein-coupled receptors 
(GPCRs) and transcription factors. 
Oncogenes are the mutated form of proto-oncogenes that become activated by genetic changes 
including; chromosomal translocations, deletions, insertions, amplifications, point mutations, 
or enhanced transcription of their genes. All these events can be instrumental in altering the 
protein structure, function, or regulation of the oncoprotein. Additionally, different viruses and 
viral proteins can transform cells via conversion of proto-oncogenes to oncogenes that later 
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fuels cell growth through controlling key cell division factors and inhibiting cellular apoptosis, 
thus allowing cells to multiply in an uncontrolled manner resulting in tumor development. 
Oncogenes or oncoproteins can be broadly categorized into several groups including non-
receptor TKs (SRC, ABL), serine/threonine kinases (AKT, RAF1), growth factors (PDGF), 
growth factor receptors (EGFR, MET, RET, TRK), small G proteins (H-RAS, K-RAS), 
transcription factors (ATF3, MYC), anti-apoptotic proteins (BCL-2, MDM2) and many more6. 
Tumor suppressor genes and their encoded proteins are involved in regulating cell growth, cell 
cycle, and proliferation; additionally, they play an essential role in apoptosis and DNA repair. 
They mainly function to guard and check the presence of any cellular abnormalities to halt 
tumor formation. In cancer, tumor suppressors are classified into five different categories as 
shown in Table 15.  
Table 1. Category of Tumor suppressors proteins and their targeted function 
Tumor suppressor type Example 
Intracellular proteins controlling or suppressing different cell cycle stages p16 and Rb 
Receptors or signal transducers that control cell proliferation 
TGFβ, hedgehog 
receptor patched 
Checkpoint-control proteins to stop cell division in case of any anomalies 
in DNA or chromosome 
p53 
Apoptosis inducers p53 
DNA repair enzymes PARP1, ATM and BRCA1 
 
Some tumor suppressor proteins may fall into several groups because of their different tumor 
suppressive functions, such as the transcription factor p53. In addition, p53 has been referred 
to as “the guardian of the genome” as it controls nearly all the steps before a cell can be 
transformed to a tumor cell7.  
1.1.3 Tumor microenvironment 
A solid tumor resembles an organ in which tumor cells and stromal cells create the tumor 
microenvironment that plays a key role in tumor formation, progression and metastasis. The 
stromal compartment may also contribute to drug resistance or unresponsiveness to 
chemotherapy. In the tumor microenvironment, apart from the stromal ECM, cells in the 
stromal compartment can be broadly categorized into two groups based on their cell of origin; 
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these include (a) tissue resident cells found before and after tumor formation and (b) tumor 
infiltrated cells that travel to the tumor site from other parts or organs of the body (Figure 2).  
 
Figure 2. Heterogeneous population of cells in a tumor microenvironment. 
Resident cells are mostly endothelial cells, pericytes, fibroblasts and occasionally neighboring 
tissue macrophages. The infiltrated cells that invade the tumor are mostly immunomodulatory 
cells that primarily respond to an immune reaction or inflammation elicited by the growing 
tumor. In most cases, tumor infiltrating immune cells includes T cells, B cells, macrophages, 
Myeloid-derived suppressor cells (MDSC), dendritic cells, and other cells from the 
hematopoietic lineage8,9. The presence of a multitude of cells in the tumor microenvironment 
initiates autocrine and paracrine signaling between the different cell types, which ultimately 
determine the fate of tumor development. 
1.1.4 Angiogenesis 
When a tumor mass increases and the diameter exceeds 1-2 mm in size, the tumor 
microenvironment experiences low oxygen pressure or hypoxia. Moreover, tumor cells go 
through a deprivation of nutrients and also accumulate cellular waste10. To avoid these 
unfavorable conditions tumor cells initiates expression of pro-angiogenic factors, which 
subsequently stimulate endothelial cells to proliferate and extend newly formed blood vessels 
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towards the tumor. A well-known angiogenic factor VEGF (vascular endothelial growth factor) 
elicits its effects on endothelial cells through binding to its cognate tyrosine kinase receptors 
(VEGFR1, VEGFR2 and VEGFR3). Activation of VEGF receptors ultimately results in 
initiation of multiple downstream signaling pathways that stimulate endothelial cell sprouting; 
endothelial cells start losing their cell-cell contacts in preparation to form an endothelial tip cell 
that can direct vascular growth through sensing pro-angiogenic factors. The leading Tip cell is 
followed by proliferating endothelial stalk cells to form a vascular sprout that ultimately form 
new blood vessels11. The newly formed vascular network supports tumor survival through 
providing oxygen and nutrients, as well as transporting waste products away from the tumor. 
Physiological angiogenesis or vasculogenesis is a phenomenon in which new blood vessels 
develop from progenitor cells which is a very unique characteristic found in embryonic 
development, tissue regeneration and the female reproductive system12. In contrast, in 
pathological angiogenesis, blood vessels develop from the existing vasculature and is a 
common feature seen in different human diseases like Irritable bowel syndrome (IBS), 
endometriosis, atherosclerosis, arthritis, diabetic retinopathy, obesity, asthma, and cancer13. 
Unlike the normal vasculature, tumor blood vessels have distinctive features; they are irregular 
and very loosely connected, making them very dilated and leaky. The leakiness of the vessels 
is associated with poor pericyte coverage on the surface of the tumor vessels causing excess 
drainage of fluid and other proteins14. Such a feature may serve good for prognosis as it may 
help better delivery of chemotherapeutic drugs to the tumor site, however, it may also enable 
tumor cells to escape the primary site and form a secondary tumor in other parts of the body9. 
Moreover, tumor cells can downregulate expression of angiogenic inhibitors 
(thrombospondins, angiostatin and endostatin) in order to favor tumor angiogenic cascades. 
Angiogenic inhibitors are known to suppress endothelial cell proliferation, migration, invasion, 
and cell adhesion molecules, thus limiting the formation of new blood vessels15. The 
relationship between angiogenesis and tumor development was first proposed by Judah 
Folkman; he described that tumor growth depends on the mutual interaction between the tumor 
and endothelial cells including the pro-angiogenic factors produced by them16. Based on this 
theory, many therapies have been developed to inhibit tumor angiogenesis or new vessel 
formation. Currently, the most common angiogenesis inhibitor found in the clinic is VEGF 
inhibitors that includes both targeted antibody (Bevacizumab) and small molecule inhibitors 
(Sunitinib and Sorafenib). However, such therapies have not been successful for cancer 
treatment due to their adverse side effects. These inhibitors not only cause microvascular 
regression in tumors but also in other organs such as thyroid, liver, kidney and GI tract resulting 
in hypothyroidism, internal bleeding, proteinuria and GI perforation17. Moreover, in a study it 
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was reported that inhibition of VEGF resulted in a pro-invasive phenotype in glioblastoma18. 
Thus, alternative treatment strategies are required to prevent tumor progression. 
Endothelial cells  
Endothelial cells play an important role in tumor development starting from tumor initiation, 
progression, invasion, dissemination and resistance to drug therapy. Endothelial cells form 
blood vessels and thus act as a medium of delivering nutrients and oxygen and eliminating 
waste products from the tumor19. In the tumor microenvironment, endothelial cells are 
activated by diverse cytokines and factors produced by tumor cells and immune cells. These 
stimulate endothelial cell proliferation and subsequently direct endothelial sprouting towards 
the tumor favoring angiogenesis20. Tumor endothelial cells are characterized by their 
expression of CD31, CD146 and ICAM-221. In the tumor, pro-inflammatory cytokines (like 
TNFα and IL1β) produced by immune cells can stimulate endothelial cells to increase the 
expression of adhesion molecules that can, in turn, support continuous inflammation and favor 
the tumor microenvironment21,22. Adhesion molecules on endothelial cells can increase the 
‘stickiness’ of the endothelium to adhere circulating immune cells and can thus promote 
inflammation23. Additionally, tumor endothelial cells possess a regulatory role in metastasis 
and have also been shown to suppress T cell function in lung cancer through the production of 
an immune suppressive factor, prostaglandin E2 
24,25. 
Pericytes  
Pericytes are mesenchymal originated mural cells commonly found covering the microvascular 
endothelial walls to stabilize the blood vessels. Additionally, they also promote proliferation 
of endothelial cells via providing them with trophic factors9. Pericytes expresses α-SMA, 
PDGFRβ, CD146 and/or NG2 depending on the type of microenvironment they are located 
in26,27. Based on marker expression and function, pericytes can be categorized into two types. 
Both Type 1 and Type 2 express PDGFRβ, CD146 and NG2 but only Type 2 pericytes express 
Nestin. In the tumor microenvironment, Type 2 pericytes are recruited to the tumor blood 
vessels to support angiogenesis28,29. Apart from vessel coverage, they also have 
immunosuppressive roles such as inhibition of cytolytic T cell function30. In cancer, increased 
pericytic coverage is linked to worse prognosis in skin cancer and renal carcinoma; moreover, 
it is also associated with chemoresistance and poor patient outcome31. Activated endothelial 
cells are known to express PDGF- which attract the PDGFRβ expressing pericytes to stabilize 
vessel integrity and to produce angiogenic VEGF and Ang-132. Limiting pericyte recruitment 
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to the vessel wall via PDGF- inhibition reduces tumor angiogenesis and metastasis33-35. 
However, although ablation of pericytes results in disorganized blood vessels leading to 
suppression of tumor growth, pericyte depletion may also open the door for metastatic 
spreading of cancer cells as is seen in breast cancer36. Therefore, targeting of pericytes for 
cancer treatment may pose to be a complicated strategy. 
Proangiogenic chemokines and cytokines 
Cytokines are small proteins that are secreted by cells to influence the behavior of neighboring 
cells or the releasing cell itself, whereas chemokines are cytokines that can attract or recruit 
other cells from distal sites/organs to the site of production. Tumor cells are known to produce 
both cytokines and chemokines to support continuous tumor cell proliferation, recruit caner-
associated fibroblasts and endothelial cells and also initiate the migration of immune cells to 
the tumor site; subsequently, these cells produce more growth factors and/or proangiogenic 
factors to drive tumor progression (Table 2)9,37. To prevent tumor development, recruited 
immune cells produce inflammatory cytokines and chemokines, of which a majority are also 
known to have pro-angiogenic properties. Additionally, infiltrated immune cells can be 
polarized by the tumor cells to produce increased levels of pro-angiogenic factors to fuel the 
formation of new blood capillaries to the tumor9.  In breast cancer, it has been shown that CCL2 
chemokine produced by the tumor cells can recruit inflammatory macrophages, which supports 
tumor angiogenesis and metastasis to the lung38. Apart from immune cells, the hypoxic 
environment in the tumor is another important regulator that instigates the expression of these 
chemokines and cytokines9. The role of hypoxia in tumor angiogenesis will be discussed in 
section 1.1.8. 
Table 2. Angiogenic chemokines and cytokines expressed in the tumor microenvironment 
Cell type Angiogenic factors 
Macrophage/TAM 
  
 VEGFA, VEGFC, VEGFD, FGF2, TNF-α, IL6, IL-1β, CXCL8, CXCL12, COX2,    
 PlGF, PDGF,  MMP7, MMP9, MMP12, Sema4D 
MDSC  VEGFA, FGF2, MMP9, CCL2 and IL-1β 
CAFs  VEGFA, PDGFC, FGF2, CXCL12, osteopontin and CSF3 
Dendritic cells  VEGF, TNF-α and CXCL8 
B cells  VEGFA, FGF2, MMP9 and IgG 
NK cells  VEGFA 
Pericytes  VEGFA, ANGPT1 and ECM components 
T cells   
TH2 cells  IL-4 
TH17cells  IL-17 
Treg cells  VEGFA 
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1.1.5 Inflammation and immune cells 
Inflammation has recently been included as an emerging hallmark of cancer4. In most solid 
tumors, the lack of oxygen and nutrients, and the recruitment of different immune cells create 
an inflammatory milieu. The inflammatory signal mainly comes from inflammatory 
chemokines and cytokines produced by immune cells recruited to the tumor as an immune 
response. Primarily, the function of the immune cells is to resolve anomalies found in the tumor 
site, clear out dead cells, and aid tissue remodeling and regeneration; however, tumor cells tend 
to overtake this process and misuse it for tumor progression. In fact, inflammatory cells 
including macrophages, dendritic cells, NK cells, T cells and B cells form an integral 
component of the tumor stromal compartment. Dvorak first reported that a wound and the 
tumor stromal compartment are similar in the sense that both contain numerous blood vessels, 
ECM producing fibroblasts, and inflammatory cells. He proposed the idea that a tumor is like 
a wound that never heals22. The link between inflammation and tumorigenesis was first 
proposed by Rudolf Virchow in 1863 after the observation that infiltrating leukocytes are a 
hallmark feature of tumors39. Inflammatory signals induced by infections has also been linked 
to cancer progression with poor prognosis40; infection causing agents include helicobacter 
pylori in gastric cancer, human papillomavirus in cervical cancer, and Epstein–Barr virus in 
Burkitt’s lymphoma. Additionally, inflammation induced by oncogene activation (Ras, Myc) 
has also been linked to different types of cancer41. Furthermore, inflammatory cells produce 
reactive oxygen species (ROS) and nitrogen that act as mutagens and cause more mutations in 
the tumor cells, in contrast to cells in the non-inflamed site42. Immune cells recruited to the 
tumor site are known to produce pro-inflammatory factors, many of which are proangiogenic 
in nature (see Table 2). The NFκB family of transcription factors significantly regulates the 
inflammatory response or inflammatory cytokine expression by immune cells, and their central 
function linked to inflammation is further discussed in section 1.1.7. 
Macrophages  
During an inflammatory response, innate immune cells are the first to act against foreign 
pathogens. These consist of different myeloid lineage cells like macrophages, neutrophils and 
mast cells. Immune cells are also known to facilitate tissue remodeling and regeneration, 
however, in tumors they support tumor vascularization and metastatic spreading. Tumor 
recruited myelogenic immune cells are very heterogeneous and they act differently depending 
on the site where they are localized, i.e. whether they are at the invading front, next to blood 
vessels, or in the hypoxic area of the tumor microenvironment43-45. Monocyte derived 
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macrophages are known to function during different stages of development, including bone 
and mammary gland formation. They are also reported to control angiogenesis in wound 
healing and tumor development46. Macrophages recruited to the tumor can portray dual 
function as pro- or anti-tumorigenic effectors.  A large number of studies suggest that 
macrophages assist in tumor development; chemokines produced in the tumor 
microenvironment such as CSF1, CCL2, CXCL12, VEGFA and SEMA3A, signal macrophage 
recruitment and polarize tumor infiltrated macrophages towards a tumor promoting type47. 
Once recruited to the tumor or infection site macrophages become activated to their classically 
activated macrophage (M1) or alternatively activated macrophage (M2) phenotypes (Figure 3). 
Macrophages are activated to their M1 phenotype mainly by the TH1 cytokines (IFNγ, TNFα 
and GM-CSF) produced by the TH1 cells and products from pathogens. Characteristically, 
classical M1 macrophages are known to produce ROS and nitrogen metabolites as well as 
different inflammatory cytokines that portray cytotoxic function on intracellular pathogens and 
tumor cells48. In the chronic skin condition psoriasis, there is an enrichment of M1 macrophages 
or TH1 response, which reduces the burden of any chance of tumor development
49. 
Alternatively, M2 macrophages are polarized mainly by the TH2 cytokines (IL4, IL13 and 
TGFβ) expressed by the TH2 cells. 
 
Figure 3. Common markers expressed by M1 and M2 like macrophages50,51. 
 
M2 macrophages are known for their major function in parasite killing and tissue remodeling48. 
Additionally, M2 macrophages are commonly found in the tumor microenvironment due to the 
enrichment of TH2 cytokines in tumors; thus, tumors educate macrophages to polarize into M2-
like macrophages. The presence of M2-like macrophages in tumors has been inversely 
correlated with disease free survival in breast cancer46,52. In addition, high levels of M2-like 
tumor-associated macrophages (TAMs) have been linked with tumor development, invasion, 
metastatic spreading and angiogenic sprouting. TAMs are known to promote angiogenesis via 
increased production of growth factors, proangiogenic cytokines and ECM degrading enzymes 
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as well as by dampening the T-cell mediated cell death response42,46,53,54.  Interestingly, the 
tumor produced chemokine CCL2 has been shown to recruit CCR2+ inflammatory monocytes 
whereas inhibition of CCL2 in turn reduces TAMs resulting in suppression of tumor 
angiogenesis and human melanoma xenograft growth38,55. Hence, TAM polarization can 
actively remodel and reprogram the tumor microenvironment; this reprogramming may 
involve increased tumor angiogenesis that promotes immune cell recruitment and activation, 
and in turn their secretome can produce an immune suppressive tumor milieu, allowing tumor 
cells to evade the adaptive immune system. 
T cells are the major effector cells that act in frontline defense against any anomalies, infection, 
microbes, viral pathogens or transformed malignant cells. The infiltration of T cells has been 
associated with either good or poor prognosis in cancer. T cells can be categorized into different 
subtypes that can play different and opposing functions in tumor development. Amongst these 
subtypes include CD4+ and CD8+ T cells. CD8+ T cells show tumoricidal function; after 
migrating and invading the tumor they become activated and produce granzyme B and perforin, 
which together mediate cytotoxicity towards the tumors cells and induces apoptosis56,57. CD4+ 
T cells can be further classified according to their different cytokine expression profiles; these 
include TH (T helper)1, TH2, TH17 and Treg (T regulatory) cells. TH1 cytokines (IFN-γ, TNF-
α, and GM-CSF) produced by TH1 cells can reprogram macrophages to their anti-tumorigenic 
M1 phenotype. In contrast, TH2 cytokines (IL4 and IL13) produced by TH2 cells can polarize 
macrophages towards the M2 phenotype, which is known to support tumorigenesis, invasion 
and metastasis in breast cancer48,58. TH17 cells secrete a wide range of pro-inflammatory 
cytokines including IL17, IL21, IL22 and CCL20. Their role in tumor immunology is quite 
controversial and their function in tumor microenvironment may rely on the surrounding milieu 
in which they reside59. However, they have been reported to enhance tumor development via 
producing immunosuppressant IL1760. In contrary, TH17 cells can be polarized into different 
subsets, which help regression of melanoma61. Treg cells are CD4+ CD25+ T cells that can 
inhibit the anti-tumorigenic immune response of CD8+ T cells via production of TGFβ and 
IL10, thus favoring tumor development59,62-64. Taken together, the function of T cells and their 
polarization depend on exposure to different cytokines and the microenvironment into which 
they are recruited. Tumor cells tend to reprogram the T cells towards the more tumor-
supporting Treg cells to promote tumor progression, angiogenesis and dissemination63. 
Increased Treg cell signatures have been found to be associated with different types of cancers 
and with worse prognosis in patients65. Adoptive transfer of tumor infiltrated 
lymphocytes/CD8+ T cells (TILs) is a very promising therapeutic approach where after 
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isolation and immunomodulation TILs are infused back into cancer patients. TIL therapy has 
recently been adopted in many clinical settings for cancer treatment66. Antibody targeted 
therapy against immune-checkpoint molecules such as PD-1, PD-L1, and CTLA-4 is another 
approach currently used in the clinic to block immune-escape of cancer cells together with 
enhanced cancer cell killing via cytotoxic T cell activation67.  
Natural killer (NK) cells arise from lymphoid progenitors and are active effector cells of the 
innate immune system. As killer cells they exert cytolysis via factors like perforin and 
granzyme B and the production of cytokines that in turn impede tumor progression. Increased 
NK cell recruitment and activation is associated with a good prognosis in different cancers68,69. 
In a tumor setting, malignant cells tend to maintain a balance between NK cell inhibition or 
activation. NK cells express multiple receptors including NKG2D, DNAM-1 and cytotoxicity 
receptors (NKp30, NKp44 and NKp46), which aid in NK cell activation via binding to specific 
ligands expressed by malignant cells to mediate cytolytic function70. DNA damage, viral 
infections, or oncogene activation induces expression of NKG2D and DNAM-1 ligands that 
result in increased NK cell recognition of the affected cell. Inhibition of these ligands leads to 
impaired NK cell mediated cytolysis71,72. In the tumor microenvironment, signals or markers 
that activate NK cells get masked and thus tumors can bypass NK cell mediated killing. 
Immune cells such as Tregs and dendritic cells are known to produce TGFβ that inhibits NK 
cell proliferation and impairs their cytolytic function73-76. Cancer associated fibroblasts (CAFs) 
are known to similarly inhibit NK cells via TGFβ which can also reduce the expression of 
perforin and granzyme B77. NK cells can express HLA-I, KIR, CD94/NKG2A and PD-1 
receptors that can block NK cell mediated killing of normal autologous cells70. They are also 
known to secret several chemokines and cytokines such as IFNγ, TNFα, GMCSF, CCL3, 
CCL4 and CCL5 to maintain interaction with the heterogeneous population of immune cells 
found in the tumor microenvironment78-80. Interestingly, tumor cells tend to reprogram the 
tumor infiltrated NK cells to produce several pro-angiogenic factors (like VEGF and PDGF) 
to support tumor development71. Melanoma cells suppress expression of NK cell activation 
receptors NKp30, NKp44 and NKG2D that impair the cytotoxic efficiency of NK cells81. 
Multiple myeloma has higher expression of PD-1, which is known to inhibit NK cells and block 
its instigated tumoricidal events82. Inhibitors of CTLA4/CD28 and PD-1/PD-L1 pathway can 
promote T cell and NK cell mediated anti-tumor activity77.  
Myeloid-derived suppressor cells (MDSCs) are a diverse group of cells that arise from the 
myeloid lineage. They are mainly immature myeloid precursor cells that include granulocytes, 
macrophages and dendritic cells. Interestingly, they become activated, recruited and expanded 
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to high numbers in response to any sustained inflammation or tumor mediated signaling, 
however, unlike other immune cells, MDSCs show immunosuppression rather than 
immunostimulation. In mice, phenotypically they are known to express CD11b and Gr1 (Ly6C 
and Ly6G). MDSC monocytic lineage have high Ly6C expression whereas MDSC 
granulocytic lineage have both Ly6C and Ly6G expression83. Solid tumors commonly produce 
GM-CSF, VEGF and TGFβ, which are known to influence polarization of myeloid cells 
towards an MDSC type and concurrently support expansion of MDSCs84,85. CCL2, CXCL8 
and CXCL12 are produced by the tumor microenvironment to increase MDSC signature or 
accumulation; this has been linked with poor survival and worse prognosis in a variety of 
cancers83. Tumor supportive MDSCs suppress the tumoricidal function of NK cells, B cells 
and cytotoxic T cells. Additionally, they produce nitrate intermediate NO and ROS, which 
results in nitration of receptors necessary for infiltration and function of T cells and NK cells83. 
Furthermore, MDSCs also favor the generation of Treg cells, promote endothelial cell 
sprouting to form new blood vessels towards the tumor and additionally produce MMPs to 
assist in invading surrounding tissue for metastatic spreading42,86-88. They can also secrete IL10 
and TGFβ proteins that can impair tumor-inhibiting immune response.  At the same time, they 
overexpress PD-L1 ligand that bind to PD-1 receptor of T cells and thus mask T cell mediated 
cytotoxic response83. Depletion of MDSC via CSF1R inhibition have been shown to enhance 
the radiotherapy response in prostate cancer patients89.    
B cells are a category of lymphoid cells that primarily function by secreting cytokines, 
producing antibodies, and presenting antigen-antibody complex in response to immune 
signals90. Because of its antigen recognizing, processing, presenting, and antibody generating 
capabilities, it forms an integral part of the immune system. It can affect other major immune 
cells including NK cells, T cells and macrophages as well as the function of other cells which 
can determine the fate of tumor development91. Similar to other immune cells, B cells are also 
found in different subtypes, which allow interactions with multiple cell types. Increased B cell 
presence along with CD8+ T cells has been linked with good prognosis in ovarian cancer92. 
However, the role of B cells in cancer is quite contradictory as different subtypes can show 
both tumor promoting and tumor suppressing activities93,94. It is now clear that similar to 
immunosuppressive T cell subtypes (Treg), B cells also have a Breg cell subtype that mainly 
exerts pro-tumorigenic effect91. Increased infiltration of Breg cells in tumors is associated with 
poor prognosis in lung, gastric and other cancers95-97. Breg cells are also known to produce 
TGFβ and IL10 that creates an immunosuppressive milieu ultimately favoring the conversion 
of CD4+ T cells into Treg cells thus supporting metastasis98. B cells recruited to prostate tumors 
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have been shown to express lymphotoxin that promotes tumor progression99. Additionally, 
Breg cells also interact with tumor-infiltrated macrophages and polarize them towards tumor 
supporting macrophages100. 
Dendritic cells are the antigen presenting cells (APCs) commonly found in different cancers 
and inflammatory sites. The role of dendritic cells in cancer is controversial as it is proposed 
that they may change their functional abilities over the course of tumoral disease progression. 
In the early stages of cancer, they may portray immunostimulatory functions including antigen 
presentation, T cell activation and differentiation. But in the late stages of cancer they may be 
reprogramed to exert tumor supporting immunosuppressive functions101. As dendritic cells are 
APCs, they communicate with other immune cells such as NK cells and B cells102. In the tumor 
microenvironment, tumor cells can polarize classical dendritic cells into tumor supporting 
subtypes (regulatory dendritic cell), which express TGFβ to fuel immunosuppressive Treg cell 
proliferation103,104. In different cancers, distinct subsets of dendritic cells have been linked with 
disease outcome; these mostly include immature dendritic cells which lack immunostimulatory 
function105.  Vaccination with distinct dendritic subtypes (cDC2s) results in tumor regression106 
and inhibition of PD-1 ligation on dendritic cells restores T cell killing capacities, opening up 
new promising paths for developing new therapeutics against cancer102. 
1.1.6 Fibroblasts in cancer 
Fibroblasts were first identified in the tumor stroma and wounds by Dvorak22. From that time 
onwards, the importance of fibroblasts in the tumor stroma and tumor microenvironment came 
into light. Fibroblasts are multipotent cells; resident quiescent fibroblasts easily get recruited 
and activated by wound healing signals, as well as by tumor produced TGFβ and CXCL12 
107,108. Fibroblasts commonly found in tumors are referred to as cancer associated fibroblasts 
(CAFs), and they constitute a major component of the tumor stromal compartment108. CAFs 
can be identified by their marked expression of αSMA, vimentin, FSP1, PDGFRα, PDGFRβ 
and DDR2109. They are known to produce important glycoproteins (laminin and fibronectin) 
and collagen I-IV that make up the ECM architecture of the tumor stroma108. On the other hand, 
they also produce ECM degrading MMPs that may allow epithelial to mesenchymal transition 
(EMT) events and enhance tumor invasion properties110. EMT is a process by which cancer 
cells can undergo multiple biochemical changes to acquire a mesenchymal cell phenotype to 
allow them to gain enhanced migratory and invasive characteristics111. Altered activation and 
pro-tumorigenic function of CAFs has been described in stomach cancer and breast 
cancer109,112. Moreover, proangiogenic VEGFA and VEGFC production by fibroblasts has 
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been associated to enhanced breast cancer cell dissemination to the lungs113. CAFs are known 
to suppress immune responses via expression of PDL1 and PDL2 to limit T cell function114. 
Moreover, the induction of several proangiogenic chemokines and cytokines such as CCL2, 
CCL5, CXCL9, CXCL10, TGFβ, TNF, IL4, IL6 and IL10 by CAFs also show its 
immunomodulatory capacities in the tumor microenvironment108. Exosomes derived from 
CAFs have been shown to promote tumor growth and drug resistance in colon cancer115. 
Furthermore, CAFs actively enhance chemoresistance in both breast cancer and prostate 
cancer116,117. 
1.1.7 Nuclear factor-kappa B 
NFκB (Nuclear factor-kappa B) is a family of transcription factors that play a significant role 
in inflammation-facilitated immune response and tumor development118. In presence of 
parasites, microbes, pathogenic particles, tissue injury, or hypoxic environment NFκB gets 
activated via pro-inflammatory cytokines TNFα and IL1β. The NFκB family is composed of 
five group members (NFκB1, NFκB2, RelA (p65), c-Rel, and RelB) that can form homo- and 
heterodimers. Unlike other members, NFκB1 and NFκB2 are proteolytically modified and 
matured into p50 and p52 respectively. These two proteins form dimers and translocate to the 
nucleus, however, since they lack a transactivation (TA) domain they cannot contribute to 
NFκB target gene transcription, but rather act as transcriptional repressors of NFκB target 
genes119,120.  
NFκB activation is regulated by a family of inhibitors known as IκB (NFκBIA, NFκBIB, 
NFκBIE and BCL3). IκB can sequester NFκB dimers in the cytoplasm and prevent NFκB 
activation and translocation into the nucleus. A group of kinases referred to as IKK or IκB 
kinase (IKBkA/Chuck, IKBkB, IKBkG and IKBkE) indirectly regulate NFκB activation 
through phosphorylation of IκB, thus preventing it to bind NFκB120. In quiescent cells, NFκB 
proteins remain bound to inhibitory molecule IκB and reside in the cytoplasm. However, any 
signal leading to ubiquitination of IκB releases NFκB, which allows NFκB complex 
translocation into the nucleus to initiate transcription of target genes (IL6 and IL8)121. The 
binding of ligands like TNFα and CD40L to their cognate cell surface receptors leads to the 
activation of NFκB that is mainly mediated via two signaling pathways, known as the canonical 
(Classical) and non-canonical (Alternative) pathway (Figure 4). In the canonical pathway, 
NFκB activation involves phosphorylation of IκB by IKK complex, which results in 
ubiquitination followed by proteasomal degradation of IκB and allows p50/p65 nuclear 
translocation. Non-canonical NFκB activation signaling involves phosphorylation and 
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proteolytic modification of the larger precursor p100, which ultimately matures into the smaller 
precursor p52 and leads to nuclear translocation of the RelB/p52 heterodimer122. 
 
Figure 4. Classical and alternative NFκB signaling pathway. 
NFκB inhibition confers reduced number of mammary stem cells, vascularization, macrophage 
recruitment and thus decreased progression of HER2-neu–induced breast cancer123.  In the 
tumor microenvironment, NFκB inhibition not only impedes anti-apoptosis activities but also 
shifts the macrophage ratio towards M1 phenotype via suppressing M2 macrophage 
polarization and thus aids tumor regression124,125. Constitutive activation of NFκB is commonly 
found in many solid cancers where it supports tumorigenesis via transcription of anti-apoptotic 
genes, regulation of EMT, upregulation of MMPs, degradation of ECM, immune evasion, and 
metastatic spreading. Activation of NFκB as a result of mutations in the upstream IKK-NFκB 
pathway has also been reported to support growth of myeloma, skin cancer, lung cancer and 
additionally can reverse the macrophage polarization towards M2 type which later supports 
cancer progression124,126-128. NFκB activation may support cell proliferation and inhibit 
apoptosis of cancer stem cells through supporting a pro-inflammatory milieu129,130. 
Furthermore, NFκB has also been reported to control tumor angiogenesis via enhanced 
expression of VEGF and its relevant receptor131-133. Although NFκB activation has been 
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associated with tumorigenesis, in response to stress signals, NFκB  activation can also inhibit 
tumor development through cancer cell killing via cytotoxic immune cell response134.  
1.1.8 Hypoxia and HIF1α 
Hypoxia can be defined as a state in which the tissue is deprived of sufficient oxygen. In cancer, 
it is known to play an important role in tumor development and tumor angiogenesis. In most 
tumors, the oxygen diffusion limit is approximately 1-2 mm135; when the tumor grows beyond 
this limit, the central region of the tumor usually experiences a drop in oxygen levels. The 
tumor cells in this hypoxic core then adapt to express proangiogenic factors that promote 
angiogenesis by stimulating the proliferation and migration of endothelial cells to this region. 
Moreover, it has been shown to affect the infiltration of immune cells to the tumor, the hypoxic 
environment prevents NK cell recruitment to the tumor site and allows tumor cells to escape a 
cytolytic fate, whereas, TAMs are recruited to support tumor progression135-137. The hypoxic 
microenvironment also leads to the stabilization and activation of hypoxia inducible factor 
(HIF). HIF is a family of transcription factors that includes two basic helix–loop–helix-PAS 
(bHLH) proteins, HIFα and HIF. HIFα contains an alpha subunit (HIF1α, HIF2α and HIF3α) 
and HIF contains a beta subunit (HIF1). In hypoxic conditions, members of these two 
subunits can form heterodimeric complexes that can translocate into the nucleus and transcribe 
genes containing a hypoxia response element in their promoter. Oxygen level is a determining 
factor for stability of HIFα subunits but not for HIF1β, which is constitutively expressed and 
more stable138. In general, HIFs are well known to regulate cell cycle, apoptosis, proliferation 
and expression of proangiogenic genes139-141. Under low oxygen condition, HIF1α can switch 
the metabolic pathway of cells from oxidative to glycolytic. Notably, HIF1α supports 
glycolysis via upregulating glycolytic enzymes and increasing the expression of glucose 
transporters (GLUT1 and GLUT3) to increase glucose uptake, and thus can support cancer cell 
survival138. HIF1α is the most well studied HIF family member, and has been shown to promote 
EMT whereas inhibition of HIF1α reduces migratory and invasive properties of cancer 
cells135,142. In breast cancer, HIF1α activation has been reported to be associated with increased 
metastasis and poor patient survival143. Additionally, loss of HIF1α in CD4+/CD8+ cells favors 
increased clonal expansion and expression of anti-tumorigenic IFNγ production144.  
The stability of HIF1α (Figure 5) mainly depends on its hydroxylation mediated by PHD 
(prolyl hydroxylase), which is a family of enzymes consisting of PHD1, PHD2 and PHD3. In 
normoxia, PHDs hydroxylates the proline residues P402 and P564 on HIF1α145. Following 
hydroxylation, a tumor suppressor adaptor protein pVHL (von Hippel-Lindau), that acts as a 
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substrate recognition component of an E3 ubiquitin ligase complex, binds to HIF1α. The E3 
ubiquitin ligase complex includes other binding partners Elongin B and C, RING-box protein 
1 (Rbx1) and Cullin 2 (Cul2) and together form the ECV complex, which catalyzes the 
polyubiquitination of HIF1α to allow for proteasomal degradation. 
 
Figure 5. Schematic pathway of HIF1α activation and transcription of target gene. 
Ubiquitination involves the collective action of three enzymes E1, E2 and E3. E1 activates 
ubiquitin and transfers it to E2. E3 conjugates with the ubiquitin bound E2 and finally transfers 
ubiquitin to target proteins146,147. Since pVHL plays a pivotal role in mediating HIF1α 
degradation in normoxic conditions, the loss or mutation of pVHL has been shown to lead to 
HIF1α activation and associated tumor development, most often in renal carcinoma145.  
PHD enzymes use molecular oxygen to hydroxylate the proline residue on HIF1α; low oxygen 
conditions prevent PHD’s catalyzing activity, resulting in HIF1α stabilization, accumulation 
and translocation to the nucleus (Figure 5). After nuclear translocation, HIF1α forms a 
heterodimer with HIF1β that binds to the hypoxia response elements (HRE) and induces 
subsequent transcription of target genes related to apoptosis, metabolism, survival and 
angiogenic factors such as VEGF, FGF2, TNFα and CXCL8137,148 (see Table 3 for additional 
target genes). Similar to HIF1α, HIF2α is also regulated in an oxygen dependent manner 
whereas HIF3α is known to be a repressor of both HIF1α and HIF2α77. Interestingly, HIF1α 
 18 
may even be activated in absence of hypoxia through inflammatory NFκB signaling; moreover, 
NFκB has also been reported to be activated by HIF1α149,150.  
 
1.2 P53 FAMILY OF TRANSCRIPTION FACTORS 
The p53 family of transcription factors consists of the tumor suppressor p53 and its paralogs 
p63 and p73. All family members share structural homology in the transactivation domain 
(TAD), oligomerization domain (OD), and highest degree of homology in the DNA binding 
domain (DBD), suggesting that all p53 paralogs can bind to the same target gene promoters.  
Figure 6. Structural similarities among p53 family members (percentage refers to amino acid 
sequence identity). 
Additionally, p63 and p73 also have a sterile alpha motif (SAM) domain, which is absent in 
p53 (Figure 6). Nine different mRNA isoforms are known to encode p53, as a result of 
alternative splicing, alternative promoter usage and additionally alternate translation initiation 
sites which lead to the translation of around 12 distinct protein isoforms151. Unlike p53, p63 
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and p73 are mainly expressed in different isoforms using two different promoters and 
alternative splicing at the c-terminal domain. Considering p53’s tumor suppressive role and 
structural homology, other family members have been speculated to have similar function. 
In a vast majority of cancers, p53 is frequently found to be mutated whereas mutation in p63 
and p73 is quite rare. Notably, p53 has been referred to as ‘the guardian of the genome’ due to 
its ability to prevent cancer development by protecting the genome from genotoxic stress152. 
As a tumor suppressor, wild type p53 regulates genomic integrity, cell cycle checkpoints, 
proliferation, differentiation, senescence and cell death mechanisms including apoptosis, 
whereas mutant p53 exerts a tumor promoting function153. Intriguingly, p53 knockout (KO) 
mice predispose to spontaneous tumor development whereas mice deleted for the p63 gene 
show abnormalities in limb and skin development. Mice that lack all p73 isoforms, mainly 
show developmental problems related to the brain154-156. The phenotypes of p73 isoform 
specific knockout mice are discussed in section 1.3.3 ‘Role of p73 in development and other 
disease’. 
1.3 THE P73 GENE 
1.3.1 Discovery of p73 
Mourad Kaghad et al. first discovered TP73 gene in 1997 and reported it to be located on 
chromosome 1p36, a region commonly deleted or silenced in pancreatic cancer, 
neuroblastoma, melanoma, breast carcinoma and hepatocellular carcinoma, suggesting this 
gene’s potential role as a tumor suppressor157. The TP73 gene spans 65 kb composed of 14 
exons; being a p53 homolog, p73 can transcribe similar genes including those related to cell 
cycle checkpoints and apoptosis, thus demonstrating tumor suppressive function when p53 is 
not functional or absent in cells158,159. Unlike p53, p73 is rarely mutated in cancer suggesting 
an ‘alternative backup’ by the cell to avoid malignancy159. Despite having tumor suppressive 
function, p73 also possesses other functions in metabolism, fertility and neuronal biology160-
162.  
1.3.2 P73 and its isoforms 
The role of p73 as a tumor suppressor is more complicated than originally thought due to the 
opposing functions of its isoforms. The p73 gene expresses two different categories of proteins; 
full-length isoforms (TAp73) that act as transcription factors and N-terminal truncated variants 
(ΔNp73) that lack the TAD resulting in transcriptionally inactive isoforms which instead 
function in a dominant negative manner like oncogenes. These isoforms mainly arise due to 
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the usage of two alternate promoters; the upstream P1 promoter generates TAp73 isoforms, 
whereas the downstream P2 promoter yields the ΔNp73 isoforms. To add more complexity, 
mRNA splicing at exon 2 and/or 3 gives rise to more isoforms including ΔEx2p73 and 
ΔEx2/3p73, which exert functions similar to the ΔNp73 isoforms, whereas, alternative splicing 
at the C terminal end results in p73 isoforms denoted as α, β, γ, δ, ε, ζ and η (Figure 7). The 
full length α isoform is the longest with a SAM domain while the δ isoform is the shortest163. 
In-silico analysis predicted the presence of even more isoforms, however whether they are 
transcribed as proteins is still unclear164. 
TAp73 is often silenced due to promoter hyper-methylation in many hematological cancers, 
whereas oncogenic ΔNp73 is dominantly overexpressed in many types of solid cancers and is 
significantly associated with poor patient prognosis. In line with this, full-length TAp73 
isoforms are reported to portray tumor suppressive function whereas ΔNp73 exerts tumor 
promoting function165,166. Therefore, a balance of these isoforms is very crucial in 
tumorigenesis as is portrayed in acute promyelocytic leukemia (APL), where a high 
ΔNp73/TAp73 ratio in favor of ΔNp73 correlates with shorter overall survival167. 
Figure 7. Schematic map to denote different p73 isoforms and distinct promoters. 
1.3.3 Functional role of p73 isoforms 
In cell cycle and checkpoints 
Cell cycle regulatory proteins are actively involved in monitoring different checkpoints during 
cell division. In cancer or cell transforming events, these regulatory proteins, or in other words 
tumor suppressor proteins, are lost, silenced, or mutated, resulting in uncontrolled cell division 
and proliferation. Under normal conditions, cell cycle progression is strictly controlled and 
advanced through four different (G1, S, G2 and M) phases under the regulation of a group of 
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serine/threonine kinases known as cyclin-dependent kinases (CDKs) and their activation 
modulatory subunit cyclins168. In this regard, CDKs and cyclins form complexes that 
phosphorylate target proteins in order to allow cell cycle to proceed; in case of TAp73, cyclin 
A/CDK1/2, cyclin B/CDK1/2 and cyclin E/CDK2 complexes phosphorylate TAp73 and in turn 
represses p73’s target gene expression169. Upon genotoxic stress signals, TAp73 actively 
facilitates cell cycle arrest in G1 and G2/M checkpoints via transactivation of the p53 target 
gene p21 and GADD45170,171. Moreover, TAp73 has also been shown to accumulate in 
genomic stress or DNA damage and induce upregulation of its pro-apoptotic target gene Bim, 
which in turn induces mitotic cell death to prevent any anomalies during mitosis172,173. In 
addition, TAp73 also regulates the mitotic phase of cell division via controlling spindle 
assembly checkpoint (SAC) complex proteins Bub1, Bub3 and BubR1. Conversely, loss of 
TAp73 leads to genomic instability resulting in aneuploid cells and lung carcinoma in mice174.  
Transformation / oncogenesis  
N-terminal truncated p73 isoform ΔNp73 and ΔNp73-like ΔEx2/3p73, favor oncogenic 
transformation in mice. Tumorigenicity is promoted via upregulation of ΔN isoforms or via 
coordinating together with other oncogenes (E1A, Ras and Myc)175,176. On the contrary, TAp73 
prevents anchorage independent growth whereas oncogenic Ras downregulates TAp73 to favor 
cellular transformation175. In support of proliferative advantage, ΔNp73 may also facilitate 
phosphorylation-mediated Retinoblastoma (Rb) protein deactivation, which in turn results in 
increased E2F signals and proliferation of fibroblasts177.  
Apoptosis and cell death 
Apoptosis or programmed cell death is a tightly regulated process and crucial for embryonic 
development and to maintain cellular homeostasis. Apoptotic cells acquire distinctive features 
including cell shrinkage, blebbing, chromatin condensation, mitochondrial swelling and 
fragmentation of nuclear DNA. Apoptosis can be mediated through two pathways, the extrinsic 
and intrinsic pathways. The extrinsic or death receptor-mediated pathway gets activated upon 
ligation of extracellular proteins to the death receptor, which subsequently leads to the 
activation of initiator caspase 8. The intrinsic or mitochondrial mediated death pathway is 
accompanied by defective mitochondrial membrane potential which instigates cytochrome c 
release and subsequently initiator caspase 9 activation. Activation of the initiator caspases leads 
to activation of a cascade of effector caspases (caspase 3, 6 and 7). Effector caspases can cause 
cleavage of a wide variety of cellular targets including cytoskeletal scaffold proteins, DNA 
repair proteins and housekeeping enzymes. They can also activate the DNAse activity of CAD 
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(caspase activated DNAse) by cleaving ICAD (inhibitor of caspase activated DNAse) that can 
fragment DNA to cause cell death178,179.  
The p73 isoform, TAp73 is known to regulate apoptosis via transcription of several pro-
apoptotic genes similar to p53. In contrast, ΔNp73 competes with TAp73 and/or p53 for 
binding to the same target genes resulting in impaired TAp73 and p53-mediated transcription 
and ensuing anti-apoptotic function.  TAp73 can facilitate cell death through both the extrinsic 
and intrinsic apoptotic pathways. Similar to p53, p73 activation upregulates death receptors 
CD95, TNF-R1, TRAIL-R1 and TRAIL-R2 along with caspases-3, -6 and -8 activation, which 
demonstrates TAp73’s role in the extrinsic apoptosis pathway. In contrast, ΔNp73 can block 
the transcriptional activity of TAp73 and p53, thus inhibiting their pro-apoptotic function and 
attenuating cell death180-185. TAp73 can also actively drive mitochondrial-mediated apoptosis 
via transactivating pro-apoptotic BH3-only proteins (BAX, NOXA, PUMA, BAD and BIK) 
and other apoptotic cofactors (p53AIP1, PERP and RanBP9)158,186. 
Autophagy and senescence  
Autophagy is a stress-induced mechanism of non-apoptotic cell death via lysosomal 
degradation of the intracellular organelles and other cellular contents. However, it is known to 
be engaged in both tumor promotion and suppression depending on the environment of resident 
cells187. TAp73 regulates expression of DNA damage regulated autophagy modulator 1 
(DRAM), but surprisingly, TAp73-mediated formation of autophagosome resulting in 
autophagy was found to be independent of DRAM activation. In the same study, there was no 
effect of ΔNp73 on starvation-induced autophagy188. In another study, TAp73 was shown to 
transactivate autophagy related gene and protein ATG5 expression independent of p53189. In 
addition, knockdown of p73β significantly reduces expression of autophagy markers in breast 
cancer cells190. 
TAp73 has been shown to have contradictory roles in senescence. As a tumor suppressor, 
TAp73 and its target gene p21 cooperates with RNPC1 to regulate premature cellular 
senescence in absence of p53; however, Du et al. showed that TAp73 depletion confers cellular 
senescence162,191. In agreement with the latter study, another report showed that TAp73 
negatively regulates cellular senescence through Cytochrome C oxidase subunit IV (Cox4i1) 
activity and ROS generation192.   
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In metabolism 
p73 and its isoforms play a vital role in regulating cellular metabolism. In a study investigating 
mouse primary cortical neurons, it was shown that p73 isoforms differentially affect the 
glycolysis pathway, which is essential for the survival of neuronal cells; loss of TAp73 
enhanced glycolysis with increases in intracellular glucose uptake, whereas ΔNp73 deficiency 
decreased glucose metabolism193. Loss of TAp73 can also affect cellular bioenergetics through 
mitochondrial dysfunction. A study has shown that TAp73 knockout cells have lower basal 
ATP levels as a result of impaired oxidative phosphorylation; in support of the previous study, 
decreased oxidative phosphorylation is thought to be linked to glucose addicted cells with 
increased glycolysis activity. The mechanism by which TAp73 is thought to control 
mitochondrial function is through the transcription and expression of Cox4i1, and loss of 
TAp73 leads to reduced expression of Cox4i1 which in turn compromises the activity of 
complex IV of the electron transport chain leading to oxidative imbalance, ROS generation and 
consequential mitochondrial dysfunction192.  
In angiogenesis 
Angiogenesis is one of the most preliminary steps tumor cells adopt to feed the tumor niche 
with oxygen and nutrients and to aid evasion from the primary tumor site. To promote 
angiogenesis, tumor cells produce chemokines and cytokines that induce blood vessel 
sprouting towards the tumor site. Studies in mouse models have shown that TAp73 suppresses 
carcinogen-induced tumors and tumor vascularization194 whereas hypoxia induced ΔNp73 
inversely promotes tumor angiogenesis via regulation of VEGF-A195. Additionally, ΔNp73 was 
shown to control the migration and vascular network forming capacities of endothelial cells 
through the regulation of VEGF and TGFβ signaling196.  
In metastasis  
Metastasis can be defined as the dissemination of cancer cells to distant organs. Prior to 
metastasis, tumor cells acquire invading or migratory phenotypes through reprogramming from 
epithelial to mesenchymal state that aid cancer cells to propagate more easily to distant sites. 
The p73 isoform TAp73 can inhibit the migratory property of tumor cells through the 
regulation of a number of factors. TAp73 can transactivate the microRNAs miR-34a and miR-
3158, which in turn downregulate the EMT associated targets vimentin, β-catenin and lef1197. 
In a study conducted by Rodhe et. al., it was shown that TAp73β can induce p57 (Kip2) 
expression which in turn inhibits the actin cytoskeleton dynamics of tumor cells thereby 
reducing their motility198. The inhibitory role of TAp73 in cell migration and invasion has also 
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been portrayed via its induction of forkhead transcription factor (FOXF1), which in turn 
regulates the transcriptional activity of E-cadherin. E-cadherin is known to maintain cell 
polarity and epithelial structure, and its decrease may promote tumor cell motility and 
invasion199. In pancreatic carcinoma, TAp73 was shown to control TGF-β signaling to block 
epithelial to mesenchymal transition whereas its loss led to increase in EMT events200. 
Selectively TAp73 loss, but not ΔNp73, exhibits increased migratory capacities and EMT 
phenotypes with increased expression of Snail-1, Slug and Twist coupled with downregulation 
of E-cadherin by MCF10A cells201,202. In contrary to TAp73 function, ΔNp73 has been shown 
to support tumor invasion and metastasis cascades through EPLIN-mediated IGF1R 
regulation203. In addition, ΔNp73 like splice variants ΔEx2/3p73 was also shown to correlate 
with lymph node metastasis in colon tumors204.  
Role of p73 in drug resistance 
Among the p73 isoforms oncogenic ΔNp73 is frequently involved in cancer drug resistance. 
High expression of ΔNp73 has been linked to anti-apoptotic function, which drives 
daunorubicin resistance in childhood acute lymphoblastic leukemia (ALL)205. ΔNp73 can 
selectively block miR-205 activity and limit its inhibitory function on anti-apoptotic Bcl-2 and 
ABC transporters including ABCA2 and ABCA5, which together lead to multi-drug resistance 
by malignant melanoma cells206. ABC (ATP-binding cassette) transporters are a group of 49 
ABC genes categorized into seven subfamilies designated as A to G based on structure and 
sequence homology. They are transmembrane proteins that regulate influx and efflux of 
different molecules, including drugs and other small molecules, through the cell’s cytoplasmic 
membrane207. Interestingly, cancer cells take advantage of overexpressing these transporters to 
facilitate increased efflux of drug molecules. Among the ABC transporters, ABCB1/MDR1 
and ABCB5 have been well studied for exerting multidrug resistance in different types of 
cancer208,209. ΔNp73α can upregulate ABCB1/MDR1 expression by inhibiting p53 function to 
potentiate the efflux capacity of gastric cancer cells210,211.  
Role of p73 in development and other disease 
Apart from its role in cancer, the function of p73 has also been explored in developmental 
processes as well as in other pathologies. p73 plays a major part in neurobiology in which case 
it maintains neuronal stemness and CNS neurogenesis212. Impairment of p73 function has been 
linked with neurodegeneration in association to Alzheimer’s disease213. Apart from this, p73 
can also actively regulate keratinocyte differentiation factor as well as osteoblast and myoblast 
differentiation214-216. It is also known to regulate liver metabolism and proliferation of cardio-
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myocytes217,218. Loss of p73 has been reported to abrogate self-renewal and differentiation 
capacity of mouse neuro-progenitor cells216. In disease, p73 is involved in inflammatory 
disorders such as atopic dermatitis (AD) and gastritis219. In the study of p73 knockout mouse 
models, it has been shown that lack of expression of all p73 isoforms display severe 
developmental abnormalities including immunological, pheromone sensing, hippocampal 
dysgenesis, enlarged ventricles, and sympathetic neuronal loss. On the other hand, TAp73 and 
ΔNp73 knockout mice exhibit fewer developmental anomalies; similar to p73 KO mice, 
ΔNp73 KO mice display enlarged ventricles and loss of neurons, whereas TAp73 KO mice 
display hippocampal dysgenesis. Interestingly, TAp73 KO mice also develop spontaneous lung 
cancer suggesting TAp73’s role as a bona fide tumor suppressor166,220. Additionally, TAp73 
distinctly controls both male and female reproduction capacity166,221, and its deficiency may 
accelerate aging and irregularities in respiratory airway multiciliogenesis192,222.  
1.3.4 P73 regulation 
Transcriptional regulators of p73 that influences its activity 
Epigenetic regulation has an important contribution in the expression of different p73 isoforms 
and their respective functions. The P1 promoter contains three CpG methylation islands 
whereas the P2 promoter only has one; this suggests that methylation greatly influences the 
transcription and expression of TAp73223. Methylation patterns may shift the balance of p73 
isoforms leading to the repression or accumulation of particular isoforms. P1 promoter 
hypermethylation results in silencing of TAp73 expression in chondrosarcoma224. Notably, 
such events are frequently observed in hematological cancers225-227. However, the causal role 
or interlinked relationship of methylation pattern of P1 promoter and hematological cancers is 
yet to be understood. Interestingly, hypermethylation of the promoter can prevent binding of 
transcriptional repressors allowing constitutive expression of a particular gene. As such, 
hypermethylation of P1 promoter blocks binding of transcriptional repressor ZEB1 to the P1 
promoter allowing enhanced TAp73-mediated target gene expression in ovarian cancer228. In 
contrast, P2 promoter hypomethylation leads to increased ΔNp73 expression, which primarily 
exhibits oncogenic function, and such events are commonly seen in solid cancers229,230.  
Important functions and expression of TP73 gene depends on upstream pathways or effectors 
that can induce or repress distinct promoters that subsequently result in the differential 
expression of certain isoforms. The upstream region of the human p73 gene promoter is known 
to have regulatory binding sites for Egr-1,2,3, Spl, and AP-2231. Additionally, it also contains 
three putative binding sites for apoptosis inducer E2F1 transcription factor232. Egr-1 has been 
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reported to bind to five different binding sites in the upstream P1 promoter of the p73 gene. 
Binding to the P1 promoter leads to the transcription of TAp73 isoform, and this in turn can 
enhance apoptosis and repress tumor cell growth. However, such effects have not been 
observed for the P2 promoter or P2 promoter derived ΔNp73232,233. Similarly, E1A also 
selectively transactivates P1 promoter driven TAp73 expression but not ΔNp73234. Sp1 binding 
sites have been shown to be present in both the P1 and P2 promotors; although Sp1 binding to 
P1 promoter positively regulates TAp73 expression, no such direct interaction was found for 
P2235.  
The Zinc Finger protein (ZEB) can directly bind to p73 genes and transcriptionally repress p73 
expression214. ΔNp73 promoter contains a putative binding site for the tumor suppressor HIC1 
(Hypermethylated In Cancer) and binding of HIC1 to the P2 promoter portrays transcriptional 
repression of ΔNp73 isoform in gastric cancer236. To add more, oncogenic c-MYC physically 
interacts with TAp73, which indirectly prevents TAp73-mediated target gene BAX 
activation237. Interestingly, both TAp73 and p53 are found to transactivate transcription of P2 
derived ΔNp73 isoform which in turn inhibits their activity, suggesting a negative feedback 
loop or dominant negative property of oncogenic ΔNp73238-241 .  
Regulators that increase p73 stability 
Post-translational modification plays a very crucial part in determining p73 stability, 
degradation and biological function. In DNA damage stress responses, physical interaction of 
p73α with Pin1 and acetylation of p73α by p300 increases p73α’s stability followed by 
increased apoptotic functions242,243. c-Jun N-terminal kinase (JNK) and checkpoint kinase 1 
(Chk1) driven phosphorylation enhances p73α target gene transcription to mediate cell cycle 
arrest or cell death in response to any genotoxicity244,245. In parallel, c-Abl, a non-receptor 
tyrosine kinase, also phosphorylates p73 proteins to increase stability of both TAp73 and 
ΔNp73 isoforms246. Moreover, PIAS-1 sumoylates p73α to potentiate p73 stability, but 
surprisingly blocks its transcriptional activity247. p73 has also been shown to induce the Mdm2 
promoter to increase Mdm2 expression which later interacts with p73α. However, Mdm2 does 
not cause p73 degradation, but rather blocks its transcriptional activity170,248,249. Inhibition of 
MDM2 and its human homolog HDM2 via Nutlin-3 can release TAp73 from Mdm2 and induce 
TAp73 mediated transcription250,251. Phosphorylation of TAp73 on threonine residue 86 by 
Cyclin/CDK complex and HCK (Src family kinase) leads to repression of p73 transcriptional 
activity169,252.  
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Regulators that influence p73 degradation 
The degradation of p73 is usually regulated by ubiquitin proteasome dependent and 
independent mechanisms253. ΔNp73 selectively undergoes proteolytic degradation induced by 
PIR2 (p73 induced ring finger protein 2), a ubiquitin protein ligase and target gene of p73254. 
In line with this, PML (promyelocytic leukemia protein) catalyzes p300-associated p73 
acetylation, which decreases p73 ubiquitination and proteasomal degradation255. In cancer, the 
FBXO45 ubiquitin ligase is upregulated in cancer cells to facilitate proteasomal mediated 
TAp73 degradation leading to impaired cell death response256, while SUMO-1, a ubiquitin 
modifier, can accelerate p73-targeted proteasomal degradation processes257. In this regard, 
chemotherapy induced stress increases pro-survival kinase PLK3 expression to abrogate 
apoptosis events via facilitating phosphorylation of TAp73 resulting in reduced TAp73 protein 
stability258. Apart from ubiquitin ligases, both TAp73 and ΔNp73 can also be cleaved and 
degraded by calpains253.  
1.3.5 Clinical importance of p73 as a target for cancer therapy 
Isoform specific knockout studies show differential roles of p73 isoforms in tumor 
development, where TAp73 loss promotes tumor development and ΔNp73 depletion shows 
impaired tumor development166,174,220. In a dominant negative fashion, ΔNp73 can form 
heteromeric complexes with TAp73 and also compete with p53 for binding to the target gene 
promoter, thus suppressing their transcriptional activity. On the other hand, ablation of ΔNp73 
releases both p53 and TAp73 to exert their subsequent apoptotic function259. Thus, maintaining 
a balance between these two p73 isoforms predicts tumor development and response to 
chemotherapy. In this regard, increasing the ratio of TAp73/ΔNp73 favors apoptotic signals, 
chemosensitivity and good prognosis183. In contrast, increasing the ratio of ΔNp73/TAp73 
correlates with reduced survival, increased chemoresistance and increased events of disease 
relapse167,183.  Interestingly, TAp73 loss is shown to correlate with EBV-mediated gastric 
cancer; and in pancreatic cancer TAp73 loss activates TGF-β signaling to promote EMT 
functions200,260. ΔNp73 has been shown to favor cancer stemness via IGF1R signaling in 
melanoma and lung cancer261. Additionally, ∆Np73 upregulation is associated with poor 
prognosis in neuroblastoma, breast cancer, cervical cancer and lung cancer patients230,262-264. 
Moreover, higher expression of ΔNp73 together with mutant p53, is linked to poor survival 
and decreased clinical responsiveness to platinum-based therapy in ovarian cancer265. 
Overexpression of ∆Np73-like p73∆Ex2/3 variants are also aberrantly expressed in cancer and 
portray drug resistance and poor prognosis in different malignancies including breast cancer, 
colon cancer and in metastatic melanoma204,266-268.  
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As mentioned above, ΔNp73 is shown to be associated with therapeutic failure in different 
cancers where it mainly contributes to prevent apoptosis. Inhibition of overexpressed ΔNp73 
indirectly favors the balance towards TAp73 that in turn induces expression of apoptotic genes 
followed by apoptosis events. In line with this, inhibition of p73∆Ex2/3 isoform results in 
regression of melanoma growth, suggesting its tumor-promoting function269. Additionally, 
ΔNp73 and ΔNp73 like p73∆Ex2/3 variant upregulation benefits cancer cells with multi-drug 
resistance characteristics via inducing expression of multi-drug resistance genes (ABCA2 and 
ABCA5), thus protecting cancer cells from drug induced cell death206. Importantly, 
chemotherapeutic treatment frequently results in activation of TAp73 to induce apoptosis, 
however, cancer cells tend to harbor increased anti-apoptotic p73 counterparts to block TAp73 
and p53 function to support ongoing oncogenesis270. 
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2 AIMS 
The overall purpose of this thesis was to decipher novel roles of p73 isoforms in different 
processes and/or components of tumor development involving tumor angiogenesis, multi-
drug resistance and regulation of tumor microenvironment. 
Specific aims of the thesis: 
Paper I - To investigate the role of p73 isoforms in regulation of pro-angiogenic factors 
and tumor angiogenesis. 
 Paper II - To study the role of TAp73 in regulating the chemokine CCL2 and its impact 
on tumor microenvironment. 
Paper III - To uncover the molecular mechanisms by which ΔNp73 affects the protein 
stability of HIF1α. 
Paper IV - To elucidate the involvement of ΔNp73 in conferring multi-drug resistance in 
cancer. 
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3 RESULTS AND DISCUSSION 
3.1 TAP73 SUPPRESSES TUMOR ANGIOGENESIS THROUGH REPRESSION 
OF PROANGIOGENIC CYTOKINES AND HIF-1Α ACTIVITY (PAPER I) 
P73 encodes two main class of proteins of which TAp73 is the full-length isoform that contains 
transactivation (TA) domain and the NH2-terminal truncated shorter isoform ΔNp73 that lacks 
the TA domain. ΔNp73 possesses oncogenic properties whereas TAp73 functions similar to 
archetypical p53 by showing cell cycle arrest, apoptosis, tumor suppression and maintaining 
genomic stability. Among the p53 family members, tumor suppressor p53 is reported to 
regulate tumor angiogenesis via transcriptional repression of proangiogenic factors152. 
However, the role of p73 and its isoforms in tumor angiogenesis was not well studied at the 
time we conducted this investigation.  
To address the role of p73 isoforms in tumor development, we took advantage of using 
TAp73+/+ (WT), ΔNp73+/+ (WT), TAp73-/- (KO) and ΔNp73-/- (KO) mouse models from which 
we isolated primary mouse embryonic fibroblast (MEFs). We transformed the MEFs with 
E1A/H-RasV12 and used these cell lines in the current study as well as in Paper II and III. We 
found no difference in cell proliferation between TAp73 WT and KO MEFs, but upon TAp73 
loss cells acquired increased anchorage-independent growing capacity, suggesting their 
enhanced potential to grow as tumors. The knockdown of TAp73 in BJ-TE fibroblasts was also 
reported to show similar accelerated anchorage-independent growth capacity175. We next 
injected TAp73 WT and KO MEFs in immunocompromised nude mice and found that TAp73 
KO MEFs grow bigger tumors with shorter latency compared to TAp73 WT tumors. This is in 
agreement with the findings shown by Tomasini et al. where TAp73 deficient mice experience 
spontaneous lung cancer166. Interestingly, TAp73 KO MEFs tumors were very reddish in 
appearance, suggesting increased blood vessels or vascularization; this was confirmed by an 
endothelial cell marker, endomucin, staining. In contrast, N-terminal truncated ΔNp73 KO 
tumors showed decreased endomucin staining indicating ΔNp73 as a positive modulator of 
tumor angiogenesis. Moreover, studying B-cell lymphoma tumors arising from transgenic 
TAp73-/-/EμMyc and ΔNp73-/-/EμMyc mice again confirmed similar increases in endomucin 
positive blood vessels upon TAp73 loss whereas ΔNp73 deficiency reduced tumor vasculature. 
Similar to our study, Amelio et al. showed that TAp73 deficiency enhances carcinogen-induced 
tumor progression and tumor angiogenesis194, whereas Dullo et al. reported that ΔNp73 
enhances tumor angiogenesis195. 
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A common trait of all tumor cells is the ability to produce proangiogenic factors that in turn 
increase blood vessel formation and promote tumor angiogenesis. To investigate whether the 
effect of p73 isoforms in tumor angiogenesis is indeed due to factors produced by the tumor 
cells and not merely tumor size, we used a short term Tg(fli:EGFP) transgenic zebrafish 
xenograft model where we injected TAp73 WT and KO MEFs in zebrafish embryo. Due to the 
transparency of the model and ease of visualization of the developing vasculature that expresses 
GFP (green fluorescent protein), the interactions between tumor cells and the endogenous 
endothelium can be easily followed in vivo. TAp73-/- cells induced increased endothelial 
sprouting towards the injected cells, whereas ΔNp73-/- cells caused significant reduction in 
endothelial sprouting compared to WT. This data highlighted the differential role of these two 
isoforms in regulation of tumor angiogenesis.  
Morphologically, tumor induced blood vessels are very irregularly branched and markedly lack 
pericytic coverage that allows high vascular permeability or leaky tumor vessels271. To check 
whether the MEF generated tumors also portrayed vascular permeability we injected high 
molecular dextran prior to tumor isolation. We observed extravascular dextran leakage, 
suggesting increased vascular permeability, in TAp73 KO tumors compared to WT. Abnormal 
tumor blood vessels are also characterized by reduced cell-cell contacts and junction molecules 
like VE-cadherin272. Tumor produced angiogenic factors like VEGF, FGF and angiopoietin 
have been reported to portray similar reduction of VE-cadherin junctions and leaky vessels 
which are known to support tumor cell extravasation and metastasis272,273. Therefore, we 
checked whether TAp73 KO MEFs produced factors that could impair VE-cadherin junctions 
in endothelial cells by adding conditioned medium (CM) from MEFs exposed to hypoxia on 
primary human dermal endothelial cells (HuDMEC). Interestingly, we found prominent 
disruption of cell-cell contact together with reduction of VE-cadherin at endothelial cell 
junctions when the HuDMECs were exposed to TAp73 KO CM. Taken together, this indicated 
to us that TAp73 deficiency stimulates tumor cells to produce proangiogenic secretomes that 
induce endothelial cell sprouting and vessel permeability.  
To determine which angiogenic factors are differentially expressed to support enhanced tumor 
angiogenesis in TAp73 KO tumors, we performed a PCR based angiogenic gene expression 
array using TAp73 WT and KO tumors. Notably, we found that 12 proangiogenic genes 
(Col18a1, Fgfr3, Cxcl1, Cxcl2, Ccl2, IL1b, IL6, Vegfc, Ereg, Tnfaip2, MMP19, and Thbs2) 
were significantly upregulated upon TAp73 loss and one gene, brain specific angiogenesis 
inhibitor (Bai1), was significantly downregulated. Some angiogenic genes (Cxcl1, Cxcl2, 
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Ccl2) that we found upregulated in TAp73 KO tumors are also known to have pro-
inflammatory function via recruiting immune cells. The effect of Ccl2 in promoting immune 
cell infiltration in TAp73 deficient tumors has been investigated in detail in Paper II. We also 
found upregulation of Vegfc in TAp73 KO tumors, which may explain how TAp73 deficiency 
results in increased vascular permeability and reduces VE-cadherin junction molecules. VEGF-
C is a classical lymph-angiogenic factor that drives endothelial sprouting or angiogenesis via 
binding to the angiogenic receptor VEGFR-2 expressed by endothelial cells and is known to 
mediate increased permeability by reducing the junction protein VE-cadherin274,275. 
Interestingly, we also show that TAp73β and p53 directly upregulates Bai1, whereas ΔNp73 
inhibits its expression. Bai1 is a transmembrane protein that is cleaved into vaculostatin, a well-
known angiogenic inhibitor276. 
The regulation of 9 genes (Cxcl1, Cxcl2, Ccl2, IL1β, IL6, Vegfc, Ereg, Tnfaip2 and Bai1) was 
further validated via qRT-PCR in TAp73 WT and KO tumors, which confirmed similar 
regulation; moreover, these genes were oppositely expressed in ΔNp73-/- tumors. This once 
again suggested that TAp73 and ΔNp73 might differentially regulate expression of angiogenic 
genes. Isoform specific regulation of angiogenic genes was also confirmed in vitro using 
TAp73 KO MEFs and ΔNp73 KO MEFs compared to their WT counterpart, and interestingly 
the regulation of the genes was further potentiated when cells were exposed to hypoxia. This 
result suggested that expression of angiogenic genes is indeed from the tumor cells and not 
merely from the stroma and that p73 is involved in regulation of hypoxia-induced angiogenic 
gene expression. 
Next, we validated our findings in human breast cancer and lung cancer cell lines in which 
knockdown of TAp73 led to increased expression of angiogenic genes, which again was further 
elevated in hypoxia. Considering the involvement of hypoxia in regulation of proangiogenic 
genes that we observed in our results, we looked into the TCGA breast cancer patient sample 
dataset to identify whether we could recapitulate similar gene signatures linked to the p73 
isoform. However, we focused our dataset analyses only for ΔNp73 and not TAp73, 
considering that ΔNp73 is the most abundantly expressed isoform in cancer164. Moreover, 
higher expression of ΔNp73 has also been correlated with worse prognosis in breast cancer204. 
Therefore, we separated the patient groups based on high expression or no expression of ΔNp73 
and performed GSEA. Interestingly, we found that hypoxia and angiogenesis genes were 
highly enriched in patients who had high expression of ΔNp73. 
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Most solid tumors experience hypoxic environments after the tumor size reaches a certain limit, 
and this hypoxic event induces the expression of HIF1α, a central regulator that controls distinct 
biological pathways including angiogenic gene signature.  Upon hypoxia, HIF1α is stabilized 
and translocated into the nucleus where it binds to Hypoxia Response Elements (HRE) and 
confers transcription of target genes. Therefore, we looked in depth to see whether the 
upregulated proangiogenic genes in TAp73-/- cells have a HRE in their gene promoter; indeed, 
we found that all the genes had HRE’s in their promoters. By performing ChIP for HIF1α with 
TAp73-/- MEFs grown in hypoxia, we discovered that HIF1α actively binds to these promoters, 
except for Cxl2, to activate transcription of the proangiogenic genes. This was further 
confirmed upon siRNA-mediated HIF1α knockdown in TAp73-/- MEFs grown in hypoxia, 
which resulted in decreased expression of proangiogenic genes. Together, our data 
demonstrated that TAp73 represses HIF1α dependent expression of proangiogenic genes. 
Additionally, we investigated whether TAp73 knockdown or overexpression could influence 
HIF1α levels. We found that TAp73-/- MEFs had increased HIF1α protein accumulation, 
whereas the opposite was observed in ΔNp73-/- MEFs. Knockdown of TAp73 in MCF7 breast 
cancer cells showed similar upregulation of HIF1α, whereas overexpression of TAp73β 
downregulated HIF1α protein levels.  Similar to our findings, Amelio et al. reported that TAp73 
suppresses tumor angiogenesis via promoting HIF1α degradation. Herein, TAp73 functions as 
a scaffold protein for HIF1α and facilitates mouse-double-minute-2 (MDM2)-mediated 
polyubiquitination and subsequent proteasomal degradation of HIF1α, similar to the 
mechanism of HIF1α degradation shown by p53194,277. However, in contradiction to our 
findings, Dullo et al. reported that hypoxia induced HIF1α blocks Siah1 which in turn leads to 
TAp73 stabilization and subsequent increased angiogenic target gene activation and 
angiogenesis, thus concluding that TAp73 promotes tumor development and angiogenesis278. 
A possible explanation for the differing results may be due to the use of different mouse models 
that are characterized by different immune components. In their study, they used a SCID mouse 
model that lacks T cells, B cells and NK cells whereas in our studies we used Nude mice which 
lack T cells but still have functional B cells and NK cells. Additionally, we verified our results 
in an immunecompetent spontaneous B cell lymphoma mouse model, where we again observed 
increased vascularization in support of our TAp73-/- MEFs tumor studies in Nude mice. 
Taken together, we demonstrated that TAp73 loss promotes tumor cells to produce increased 
pro-angiogenic factors that lead to tumor angiogenesis. This enhancement of angiogenesis 
signature is mainly conferred via increased HIF1α activity. In contrast, ΔNp73 loss leads to 
reduced tumor angiogenesis and downregulation of pro-angiogenic factors in concomitance 
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with decreased HIF1α activity. To conclude, we have discovered that TAp73 and ΔNp73 
isoforms play opposite roles in tumor angiogenesis through regulation of HIF1α activity.  
 
Figure 8. Graphical abstract showing how TAp73 and ΔNp73 are involved with HIF1α to 
regulate the expression of proangiogenic genes and subsequent tumor angiogenesis. 
3.2 TAP73 DEFICIENCY ENHANCES CCL2 EXPRESSION AND INCREASES 
INTRA-TUMORAL INFILTRATION OF TUMOR-ASSOCIATED 
MACROPHAGES (PAPER II) 
In Paper I, we reported that TAp73 deficient tumors, MEFs, and breast cancer cells have 
increased expression of proangiogenic chemokines and cytokines. Among these factors, the 
chemokine CCL2 was found to be highly upregulated. CCL2 belongs to a group of low 
molecular weight C-C chemokines that is commonly expressed by different cell types including 
myeloid, endothelial, epithelial, fibroblasts and most importantly different cancer cells. Apart 
from its proangiogenic characteristic, CCL2 is well known for its function as a macrophage 
chemoattractant and has the ability to recruit a variety of immune cells including T cells, NK 
cells and monocytes to the site of production. Tumors commonly express CCL2 to attract 
macrophages, which in turn mediate production of proangiogenic factors. These can then 
stimulate endothelial cell proliferation and migration leading to tumor angiogenesis, dampen 
the immune response and support tumor development279-281. Considering the fact that tumors 
favor recruitment of immune cells to the tumor microenvironment to support tumor progression 
and that CCL2 was upregulated in our results in Paper I, in this study we tried to explore how 
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TAp73 loss may induce CCL2 expression to promote immune cell infiltration which in turn 
drives tumor development. However, unlike Paper I, here we investigated TAp73 driven 
regulation of CCL2 independent of hypoxia.  
We used two different pairs of TAp73-/- and TAp73+/+ E1A/Ras transformed MEFs and found 
that TAp73 knockout cells harbor increased expression of Ccl2 mRNA, which was 
complemented with increased Ccl2 protein expression as shown by Western blot and ELISA.   
To assess TAp73-driven Ccl2 regulation, we reintroduced TAp73 isoforms in TAp73 knockout 
MEFs and found a downregulation of Ccl2 mRNA expression. To see if similar regulation 
could be recapitulated in cancer cell lines, we overexpressed TAp73 isoforms in two different 
murine breast cancer cells (E0771 and 4T1) and showed similar downregulation of Ccl2 
mRNA. Interestingly, for both TAp73-/- MEFs and breast cancer cell lines, TAp73 dependent 
repression of Ccl2 was mainly observed by TAp73β but not the TAp73α isoform. This may be 
explained by the structural difference between TAp73α and TAp73β. Unlike TAp73β, TAp73α 
contains an extra sterile alpha motif (SAM) and transcription inhibitory domain (TID) which 
limits the accessibility of binding partner p300/CBP to the p73 activation motif, for which 
TAp73α acquires poor transcriptional capacity compared to TAp73β282. This means that 
TAp73α and TAp73β can have differential transcriptional activities and function on the same 
target genes283,284. In agreement, a study showed that TAp73α upregulates c-Jun expression 
whereas TAp73β downregulates its expression283. 
To recapitulate similar regulation in human cell lines, we knocked down TAp73 in two breast 
cancer cell lines using two different siRNA oligos and found increased expression of CCL2 
mRNA. On the other hand, overexpression of TAp73 isoforms, particularly TAp73β, shows 
significant downregulation of CCL2. CCL2 expression negatively correlates with patient 
prognosis, and supports metastatic cascade which interferes with disease free survival in a 
variety of cancers281,285-288. High expression of CCL2 is commonly found in breast cancer, lung 
cancer, colon cancer, liver cancer and prostate cancer281,286,287. Additionally, precancerous 
senescent hepatocytes have been shown to produce CCL2 to recruit CCR2+ immature myeloid 
cells (iMCs), which upon differentiation into macrophages are responsible for the clearance of 
senescent cells; tumor cells prevent differentiation of iMCs into macrophages which in turn 
inhibits NK cell function and promotes hepatocellular cancer growth289. To verify if the 
correlation between TP73 and CCL2 holds significance in human cancers, we evaluated our 
results in clinical samples by analyzing publicly available human cancer datasets (TCGA). We 
found a significant negative correlation between TP73 and CCL2 expression in a panel of 50 
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breast cancer cell lines and three different breast cancer patient datasets. In agreement, datasets 
from liver cancer, lung cancer and colon cancer also showed similar negative correlation 
between TP73 and CCL2. Together, these findings consolidate the idea that TAp73 negatively 
regulates CCL2 expression. 
To explore the precise mechanism of Ccl2 regulation in more depth, we used a Luc-reporter 
tagged Ccl2 promoter construct and performed a reporter assay along with overexpression of 
TAp73 and ΔNp73 isoforms. Notably, we again found that TAp73β but not TAp73α or ΔNp73 
isoforms, represses Ccl2 promoter activity. To decipher whether TAp73 driven regulation of 
Ccl2, is conferred via binding to the Ccl2 promoter, we analyzed the Ccl2 promoter region 
using MatInspector transcription factor binding tool and found no binding sites for TAp73. 
This led us to think that TAp73 may indirectly regulate expression of Ccl2. Interestingly, the 
murine Ccl2 promoter is reported to contain four putative NFκB binding sites290 . It has been 
reported that Ccl2 is a transcriptional target gene of NFκB and that the aberrant expression of 
both has been commonly observed in cancer291,292. To verify whether the NFκB-binding motifs 
found in the Ccl2 promoter have any role in TAp73 mediated Ccl2 promoter activity, we 
mutated each NFκB binding site and performed reporter assays with overexpression of TAp73α 
or TAp73β. Intriguingly, we discovered that deletion of NFκB binding site 1 or 2 results in 
enhanced Ccl2 promoter activity, implicating that both binding sites are important for NFκB 
mediated Ccl2 suppression. However, the reduced activity of the Ccl2 promoter by TAp73β 
was still evident even after loss of the binding sites. Additionally, deletion of either NFκB 
binding site 3 (NKB-3) or 4 (NKB-4) significantly reduced Ccl2 promoter activity, which was 
still reduced upon overexpression of TAp73β.  Furthermore, a very strong reduction of Ccl2 
promoter activity was seen when both binding site NKB-3 and NKB-4 were collectively 
removed, and no further suppression was observed upon co-expression with TAp73β. Taken 
together, we showed that NKB-3 and NKB-4 sites are important for Ccl2 promoter activation 
and TAp73β can impede NFκB mediated transcriptional activation of the Ccl2 promoter. 
To understand the molecular interaction between TAp73 and NFκB, we transfected NFκB 
consensus binding site reporter constructs into TAp73 WT and KO MEFs.  We found that 
TAp73 KO MEFs showed increased NFκB transcriptional activity; this finding was further 
complemented with qRT-PCR data showing increased expression of NFκB target genes 
(Cxcl1, Cxcl5, and Cxcl10) in TAp73 KO MEFs compared to WT. To further assess whether 
the increased NFκB activity observed in the TAp73-/- MEFs could result in increased Ccl2 
expression, we inhibited NFκB activity in MEFs using SC514 and performed qRT-PCR and 
ELISA for Ccl2. Mechanistically, SC514 mainly inhibits IKK2 to stabilize IκBα/NFκB binding 
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which ultimately blocks translocation of NFκB subunits into the nucleus and thus prevents 
NFκB-mediated transcription293. We observed higher levels of Ccl2 mRNA as well as secreted 
Ccl2 protein from TAp73 deficient cells, whereas inhibition of NFκB impeded this 
upregulation and normalized Ccl2 levels closer to wild-type MEFs. This suggested that TAp73 
loss favors increased NFκB activity resulting in higher expression of Ccl2. 
The NFκB family is composed of five members including NFκB1 (p105), NFκB2 (p100), RelA 
(p65), c-Rel, and RelB. Among them, NFκB1 (p105) and NFκB2 (p100) undergo proteasomal 
modification and are cleaved into p50 and p52 respectively. The cleaved subunits and other 
family members commonly form homodimers or heterodimers prior to nuclear translocation 
and transactivation of targeted genes. Notably, NFκB-mediated Ccl2 promoter activation has 
been reported to be induced by the p65/p65 or p65/p50 dimers290. Therefore, we investigated 
the expression of these NFκB subunits in TAp73+/+ and TAp73-/- MEFs via western blot. 
However, we found no differences in p65 or p50 expression. Upon NFκB activation, p65 
together with its dimeric partner is known to translocate into the nucleus to activate target 
genes. Therefore, we checked p65 expression via immunohistochemistry (IHC), but found no 
difference in nuclear translocation of p65 between TAp73 WT and KO MEFs. Generally, 
NFκB activity is determined via several positive (IKBkA/Chuck, IKBkB and IKBkE) and 
negative (NFκBIA, NFκBIB, NFκBIE and BCL3) regulators including transcriptional 
repressor (p50/p52). Therefore, we checked these regulators in the TAp73+/+ and TAp73-/- 
MEFs via qRT-PCR and revealed no significant difference in gene expression except for 
NFκB2. NFκB2 is a precursor protein that is proteolytically modified and matured into p52 
subunits which lack the TAD, and acts as a transcriptional repressor against NFκB 
activity294,295. In line with our qRT-PCR results for NFκB2, we observed distinct 
downregulation of p52 protein in TAp73 KO MEFs compared to WT. Thus, our results indicate 
that TAp73 deficiency reduces transcriptional repressor p52 that in turn favors increased 
NFκB-mediated transcriptional activity and subsequent target gene expression of Ccl2.  
As mentioned previously, the tumor microenvironment can induce the expression of CCL2 to 
potentiate infiltration of immune cells that can in turn promote tumor progression. In breast 
cancer, CCL2 has been shown to recruit CD11b+/Ly6C+/Gr+ inflammatory monocytes to 
promote metastasis events via supporting enhanced angiogenesis38. CCL2 also instigates CCL3 
expression by metastasis-associated macrophages that in turn support increased events of lung 
metastasis285. Since TAp73 deficiency results in enhanced expression of Ccl2, we hypothesized 
that TAp73 knockout tumors may have increased recruitment of macrophages into the tumors. 
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To verify this, we used TAp73-/- and TAp73+/+ MEFs generated tumors raised in Nude mice. 
Tumor sections stained for F4-80 pan macrophage marker showed that TAp73-/- tumors 
harbored increased macrophage recruitment compared to WT tumors. Additionally, we also 
performed FACS analysis for F4-80 and CD11c macrophage markers and once again observed 
increased F4-80+/CD11c+ double positive macrophages recruited to the TAp73 KO tumors 
compared to WT tumors. Our data demonstrated that TAp73 loss favors increased macrophage 
recruitment to tumors.  
Different factors produced by the tumor microenvironment can reprogram macrophages 
towards tumor supporting TAMs rather than tumor inhibiting type. The recruited TAMs can 
dampen the immune response and also produce more proangiogenic factors to support tumor 
development47. In line with this, CCL2 has been shown to polarize CD11b+ macrophages to 
M2 like macrophages (CD206+ TAMs)296. Therefore, we checked tumor sections for TAM 
marker CD206 to determine whether the increased macrophage population observed in the 
TAp73 KO tumors were indeed TAMs. CD206 staining confirmed that macrophages in the 
TAp73-/- tumors were in fact mainly tumor-associated macrophages. FACS analysis for double 
positive CD206+/F4-80+ populations again portrayed that TAp73-/- tumors were enriched with 
a higher proportion of TAMs compared to WT. By performing qRT-PCR for macrophage 
markers, we again showed that TAp73 KO tumors have increased expression of TAMs marker 
Mrc1 (CD206) and Arg1, whereas anti-tumorigenic macrophage marker iNOS (NOS2) 
remained unchanged between both tumor types. To further validate our in vivo results in human 
clinical samples, we analyzed publicly available cancer patient datasets and confirmed a 
negative correlation between TP73 and MRC1 (CD206) expression in breast cancer and lung 
cancer.  
In summary, our study proposed a novel mechanism by which TAp73 represses transcriptional 
activation of Ccl2 via interference of NFκB activity. Moreover, TAp73 loss in tumors favors 
upregulation of Ccl2 that in turn supports increased recruitment of tumor-associated 
macrophages to support tumor development. 
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Figure 9. Graphical abstract showing CCL2 repression by TAp73 and its impact on tumor 
microenvironment. 
3.3 ΔNP73 ENHANCES HIF-1Α PROTEIN STABILITY THROUGH 
REPRESSION OF THE ECV COMPLEX (PAPER III) 
Most solid tumors often experience low oxygen tension. The hypoxia exposed tumor cells then 
start to express hypoxia inducible factor (HIF), a master regulator that regulates genes essential 
for tumor cell survival, including those related to angiogenesis and metabolism which help to 
adapt to an alternate environment. In Paper I, we demonstrated that ΔNp73 absence conferred 
reduced HIF1α stability; in this paper, we continued our study to unravel the underlying 
molecular mechanism of how ΔNp73 is involved in regulation of HIF1α stability.  
To investigate, we knocked down ΔNp73 using siRNA and shRNA targeting ΔNp73 in human 
breast cancer cell lines MCF7 and MDA-MB-231. Upon ΔNp73 knockdown, we observed 
significant downregulation of HIF1α protein compared to control cells. Intriguingly, ΔNp73 
deficiency associated downregulation of HIF1α was observed in both normoxic and hypoxic 
conditions, suggesting that ΔNp73 ablation can affect HIF1α protein stability independent of a 
hypoxic environment.  Additionally, in Paper I, we showed that ΔNp73 loss results in 
decreased HIF1α protein but not mRNA, and in this study, we again found no effect of ΔNp73 
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on HIF1α mRNA expression which suggests that ΔNp73 influences the protein stability of 
HIF1α but not the transcription of HIF1α. In line with this, our qRT-PCR data indicated 
downregulation of HIF1α target genes (VEGFA, LDHA and PDK1) concomitant to HIF1α 
protein downregulation. This suggested that ΔNp73 deficiency mediates reduction of HIF1α, 
which subsequently reduces HIF1α’s transcriptional activity. To reconfirm this regulation, we 
overexpressed ΔNp73α to determine whether higher expression of ΔNp73 could upregulate 
HIF1α protein. Indeed, we found upregulation of HIF1α protein upon overexpression of 
ΔNp73α, suggesting that ΔNp73 can positively regulate HIF1α stability. Interestingly, during 
hypoxia HIF1α can stabilize ΔNp73 via suppression of E3 ligase Siah1195. Together with our 
results, this could reflect a possible feedback mechanism between ΔNp73 and HIF1α at varying 
oxygen conditions. 
To translate our findings in vivo, we established tumor from ΔNp73 WT and KO E1A/Ras 
transformed MEFs. In line with our previous reports, we observed that ΔNp73 deficiency led 
to impaired tumor formation220. We analyzed the tumors for HIF1α and discovered similar 
downregulation of HIF1α protein in ΔNp73 KO tumors compared to ΔNp73 WT tumors. 
Considering the size difference between ΔNp73-/- and ΔNp73+/+ tumors, we examined the 
expression of HIF1α within the hypoxic region by injecting HydroxyProbe-1 in the mice prior 
to tumor isolation. Using immunofluorescence staining for HIF1α and HydroxyProbe-1, we 
again observed significant reduction of HIF1α staining within the hypoxic regions in ΔNp73 
KO tumors compared to WT. Together; our data demonstrated that ΔNp73 deficiency 
attenuates tumor induced HIF1α expression. 
The stability, accumulation and activity of HIF1α protein is regulated via post-translational 
modification cascades297. In normoxia, HIF1α levels are negatively regulated via proteasomal 
degradation and ubiquitination pathway mediated by Von Hippel-Lindau protein (pVHL). 
Since ΔNp73 deficiency results in decreased HIF1α stability, we hypothesized a possible role 
for ΔNp73 in interfering with ubiquitination of HIF1α, which in turn affects its stability. To 
study this, we inhibited the proteasomal degradation pathway using MG132 in shCtrl and 
shΔNp73 breast cancer cells. Interestingly, we observed normalization of HIF1α protein levels 
in ΔNp73 knockdown cells similar to the levels seen for control cells. Additionally, performing 
Co-IP we showed that ΔNp73 deficient cells have increased ubiquitin bound to HIF1α, 
suggesting that ΔNp73 loss leads to increased ubiquitin binding to HIF1α protein, leading to 
its ubiquitination and proteasomal degradation. This mechanism was observed for both ΔNp73 
KO MEFs and human breast cancer ΔNp73 KD MCF7 and MDA-MB-231 cells. However, in 
normoxic condition prior to ubiquitin-mediated degradation, HIF1α is first hydroxylated by a 
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group of prolyl-4-hydroxylase (PHD 1-3) enzymes which helps in recognition of HIF1α by 
pVHL, which in turn ubiquitinates HIF1α and targets it for proteasomal degradation. Among 
the PHD enzymes, PHD2 is a target gene of p53 and is well known for maintaining steady-
state levels of HIF1α. ΔNp73 is known to impede p53-mediated transcription238, suggesting 
that ΔNp73 may interfere with p53-mediated PHD2 transcription in order reduce HIF1α 
degradation and thus increase HIF1α stability. To test this theory, we checked hydroxylated 
HIF1α after blocking the proteasomal degradation machinery by MG132 treatment, and 
surprisingly found no differences in hydroxylated HIF1α protein levels between ΔNp73 control 
and knockdown cells. This indicated that ΔNp73 does not interfere with hydroxylation of 
HIF1α. 
The tumor suppressor pVHL is a multipurpose adaptor protein encoded from von Hippel-
Lindau gene (VHL) which functions as a substrate recognition subunit of an E3 ligase complex 
termed as ECV. The ECV complex comprises of pVHL, Cullin 2 (Cul2), Elongin B (Tceb1), 
Elongin C (Tceb2) and Rbx1; the complex primarily targets HIF1α for ubiquitin mediated 
proteasomal degradation in normoxic condition. During hypoxia, HIF1α does not undergo 
hydroxylation, which prevents pVHL mediated proteasomal degradation resulting in HIF1α 
accumulation, followed by increased proliferation and angiogenesis as portrayed in VHL 
disease298. Based on the fact that HIF1α stability is controlled by the adaptor protein pVHL, 
we sought to investigate whether pVHL drives ΔNp73 deficiency mediated downregulation of 
HIF1α. To confirm this concept, we performed siRNA-mediated knockdown of ΔNp73 in two 
different renal carcinoma cell lines, RCC4+VHL(with functional VHL) and RCC4 (deficient for 
VHL). Interestingly, we found no differences in HIF1α levels when pVHL remained mutated 
or nonfunctional, but in presence of functional pVHL, ΔNp73 deficiency instigated similar 
downregulation of HIF1α protein as demonstrated earlier. This implied that ΔNp73 loss 
mediated reduction of HIF1α is mainly conferred via a pVHL dependent mechanism.  
Both ΔNp73 and HIF1α are considered to be bad prognostic factors in a variety of cancers; 
high expression of these isoforms lead to poor response to drug therapy, disease aggressiveness 
and poor patient outcome in liver cancer, gastric cancer, colon cancer and breast 
cancer180,299,300. Considering their major involvement in cancer, we evaluated our results in 
patient samples to establish a link between ΔNp73 and HIF1α. By analyzing TCGA breast 
cancer dataset in paper I, we have shown that higher expression of ΔNp73 is positively 
associated with angiogenesis and hypoxia gene signatures in breast cancer patients. For the 
current study, we reanalyzed the same data and performed gene set enrichment analysis 
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(GSEA) on samples that had high levels of ΔNp73, in order to search for pathways most 
affected. We found that genes associated with ubiquitin-mediated proteolysis were 
downregulated in patients who had high expression of ΔNp73. When we looked in more depth 
for genes involved with ubiquitin-mediated proteolysis, we found that the ECV genes (RBX1, 
CUL2, TCEB1 and TCEB2) were significantly downregulated. 
Next, to validate our patient data results we ectopically overexpressed ΔNp73α in two human 
breast cancer cell lines and found similar downregulation of ECV genes as observed for patients 
who had high ΔNp73 levels. To confirm this regulation, we also knocked down ΔNp73 in the 
same breast cancer cell lines and notably found upregulation of the same ECV genes. 
Concomitantly, we also reconfirmed similar regulation in MEFs where ΔNp73 KO MEFs 
exhibited higher expression of ECV genes at both mRNA and protein levels.  Additionally, 
reintroduction of ΔNp73α in the ΔNp73-/- MEFs conversely downregulated the expression of 
ECV genes. Based on these findings, we demonstrated that ΔNp73 negatively regulates the 
expression of ECV complex members (RBX1, CUL2, TCEB1 and TCEB2) in order to interfere 
with ubiquitination of HIF1α, as confirmed in both breast cancer cells and breast cancer patient 
samples.  
Rbx1 is a RING-finger protein recruited by Cul2 that is able to recognize important E2 
ubiquitin-conjugating enzyme, which is necessary for mediating E3 ligase function of ECV 
complex298. To explore whether ΔNp73 mediated downregulation of Rbx1 results in 
accumulation of HIF1α we performed IP for pVHL in ΔNp73 KO and WT MEFs followed by 
western blot. Interestingly, we observed increased Rbx1 bound to pVHL in ΔNp73 KO MEFs 
whereas no differences were seen in pVHL binding to HIF1α. This suggested that ΔNp73 
deficient cells may have an active ECV complex pathway that aids HIF1α degradation. In line 
with these results, siRNA mediated Rbx1 knockdown showed significant upregulation of 
HIF1α protein, which remained unchanged when both ΔNp73 and Rbx1 were downregulated 
in RCC4+VHL cells that have functional VHL. Our data shows that ΔNp73 inhibits HIF1α 
ubiqutination by downregulating the ECV genes, thus impeding VHL-dependent proteasomal 
degradation of HIF1α, resulting in increased HIF1α stability and accumulation. 
In Paper I, we showed that ΔNp73 loss results in decreased HIF1α protein. Herein, we further 
unraveled this molecular mechanism, where we demonstrated that ΔNp73 controls HIF1α 
stability via regulation of ECV genes. 
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Figure 10. Graphical abstract showing ΔNp73 promoting HIF1α protein stability, resulting in 
transactivation of its target genes. 
3.4 ΔNP73 REGULATES THE EXPRESSION OF THE MULTIDRUG-
RESISTANCE GENES ABCB1 AND ABCB5 IN BREAST CANCER AND 
MELANOMA CELLS (PAPER IV) 
In Paper I, we demonstrated that breast cancer samples expressing high ΔNp73 were enriched 
for angiogenesis and hypoxia signatures. For this study, we went back to the same dataset and 
scanned for pathways that were upregulated in breast cancer patient samples that had high 
expression of ΔNp73. We filtered the dataset based on genes that were significantly 
upregulated more than two-fold in samples with high ΔNp73 expression, and performed a 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. 
KEGG pathway analysis revealed that ABC pathways were most enriched; apart from higher 
expression of ABC genes, we also found upregulation of other pathways including tyrosine 
metabolism, ECM receptor interactions, cell adhesion and focal adhesion pathways. ATP 
binding cassettes (ABCs) are transporter proteins that primarily function by importing and 
exporting different molecules within the cells. Cancer cells are known to overexpress these 
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genes in order to facilitate increased efflux of drug molecules from the cells to avoid 
cytotoxicity. Moreover, ΔNp73 has been associated with impaired drug response, impeded 
apoptotic signals and with poor patient prognosis in a variety of cancers. Therefore, considering 
the involvement of both ΔNp73 and ABC transporters in drug resistance and cancer patient 
disease outcome, we focused our study on the ABC transporters to decipher how ΔNp73 
interplays with the ABC family to exert drug resistance. 
We looked into more depth to determine which ABC genes were upregulated in the high 
ΔNp73-expressing samples. We observed significant upregulation of several ABC members 
including ABC subfamily A (ABCA5, ABCA6, ABCA8, ABCA9, ABCA10), ABC subfamily 
B (ABCB1 and ABCB5), ABC subfamily D (ABCD2) and ABC subfamily G (ABCG2). The 
association of p73 isoforms with ABC transporters has been previously reported in different 
malignancies; ABCA5 transporter is shown to be positively regulated by splice variant ΔNp73 
in malignant melanoma, whereas association of p73-isoforms with ABCB1 has been reported 
in colon cancer and neuroblastoma206,211,268. However, to the best of our knowledge, ΔNp73 
driven regulation of ABC genes in breast cancer was not previously investigated. Considering 
the high incidence of breast cancer treatment failure as a result of drug resistance, the role of 
ΔNp73 in ABC transporter regulation may shed new light into the mechanisms behind 
chemotherapeutic failure. 
To investigate the ΔNp73-driven regulation of ABC genes, we transiently overexpressed 
ΔNp73 isoform into two human breast cancer cell lines MCF7 (p53 WT) and MDA-MB-231 
(mutant p53).  Next, we performed qRT-PCR to check the expression of the top five 
upregulated ABC genes that were found to be enriched in the high ΔNp73-expressing breast 
cancer patient samples.  Interestingly, similar to the dataset results, we observed upregulation 
of ABCB1 and ABCB5 genes upon overexpression of ΔNp73α whereas expression of ABCA8, 
ABCA9 and ABCB10 were undetected in both cell lines; a possible explanation could be that 
these transporters might be expressed by other cells present in the tumor stromal compartment. 
Hence, we focused our study on ABCB1 and ABCB5 genes. In a study by Vilgelm et al., it 
was reported that ΔNp73 could upregulate ABCB1 expression via limiting p53-driven 
transrepression of the ABCB1 gene in gastric cancer211. However, here we demonstrated 
upregulation of both ABCB1 and ABCB5 genes irrespectively of p53 status. This suggests that 
ΔNp73 may mediate regulation of these transporters through interaction with other proteins or 
pathways exclusive of p53. In a study by Bao et al., it has been shown that miR-298 confers 
doxorubicin drug resistance in metastatic breast cancer through upregulation of ABCB1301; 
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whether ΔNp73 regulates miR-298 or other miRNAs to inhibit ABCB1 and ABCB5 in breast 
cancer would be interesting to investigate. 
To further verify the regulation of ABC genes, we performed shRNA-mediated knockdown of 
ΔNp73 in both breast cancer cell lines to detect whether downregulation of ΔNp73 can result 
in downregulation of ABC genes. As expected, qRT-PCR results indicated downregulation of 
ABC genes upon knockdown of ΔNp73. Furthermore, siRNA-targeted knockdown of ΔNp73 
in both cell lines confirmed significant downregulation of both ABCB1 and ABCB5 genes. 
Together, these results highlighted that ΔNp73 positively regulates ABCB1 and ABCB5 
expression in breast cancer cells. 
The high expression ΔNp73 has been reported to be associated with poor patient outcome 
following chemoresistance in a myriad of cancers including breast cancer180. Moreover, 
ABCB1 and ABCB5 have been associated to drug resistance in breast cancer through 
mediating doxorubicin efflux301,302. Taken together, these reports suggested a possible role that 
interlinked ΔNp73 and ABC transporters in developing drug resistance in breast cancer. 
Considering this, we checked whether ΔNp73 deficiency could influence the proliferation and 
efflux capacity of MCF7 and MDA-MB-231 cells upon doxorubicin treatment. We performed 
an efflux assay and found that ΔNp73 ablation leads to increased intracellular accumulation of 
doxorubicin in ΔNp73 deficient cells compared to control cells. We further confirmed the 
results with a WST-1 assay, where doxorubicin treated ΔNp73 deficient cells showed reduced 
proliferation in line with decreased efflux capacity. Collectively, our results highlighted that 
ΔNp73 deficiency impairs drug efflux capacity of breast cancer cells and sensitize them 
towards chemotherapy-induced cell death. 
Finally, to evaluate our results in another cancer type and to verify the clinical relevance of our 
findings, we investigated the correlation of ΔNp73, ABCB1 and ABCB5 in melanoma patient 
samples. We did not detect the expression of ΔNp73 in the samples, but instead found the 
expression of the ΔNp73-like p73ΔEx2/3 isoform. p73ΔEx2/3 is the predominant isoform 
expressed in melanoma, and the absence of a TA domain gives it similar function as ΔNp73267. 
Hence, we hypothesized that in melanoma p73ΔEx2/3, similar ΔNp73, may be involved with 
the regulation of ABCB1 and ABCB5 expression. Using qRT-PCR, we confirmed that 
p73ΔEx2/3-like ΔNp73 is positively correlated with the expression of ABCB1 and ABCB5. 
Next, we overexpressed p73ΔEx2/3α and p73ΔEx2/3β isoforms in SK-MEL-28 melanoma 
cells to verify our previous result. Likewise, overexpression of p73ΔEx2/3 isoforms again 
showed upregulation of ABCB1 and ABCB5, similar to our results seen for ΔNp73 in breast 
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cancer cell lines. Our data implies that in melanoma the predominant ΔNp73-like p73ΔEx2/3 
isoform mainly drives the expression of multidrug resistance genes ABCB1 and ABCB5. 
In line with ΔNp73’s positive role in tumor angiogenesis shown in Paper I, here we again 
demonstrate ΔNp73’s active role in development of drug resistance via controlling expression 
of multidrug resistance genes.  
 
Figure 11. Graphical abstract to show how ΔNp73 mediates drug resistance. A. Low ΔNp73 
expression scenario B. High ΔNp73 expression scenario. Orange color denotes ABC 
transporter, pink color for doxorubicin and brown color for ΔNp73. 
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4 CONCLUSION AND FUTURE PERSPECTIVES 
Tumor development occurs through different stages including avoidance of cell cycle arrest 
and apoptosis, adaptation to harsh hypoxic environment, bypassing immune surveillance, 
forming a niche and reinforcing new blood vessels. Additionally, tumor cells can take 
advantage of cellular efflux machinery and enhance the expression of multi-drug resistance 
proteins to avoid drug mediated cytotoxicity. In this thesis, some of these points were addressed 
to decipher the role of p73 isoforms in tumor development. 
In Paper I, we have shown that TAp73 suppresses expression of several pro-angiogenic factors 
whereas TAp73 loss favors tumor cells with increased expression of these factors, which in 
turn results in increased tumor vascularization. On the other hand, oncogenic ΔNp73 loss 
results in decreased tumor vascularization and decreased expression of pro-angiogenic genes. 
This demonstrates a novel mechanism by which different p73 isoforms show opposite 
functions in regulating tumor angiogenesis. Additionally, we showed that TAp73 regulates 
proangiogenic factors via inhibition of HIF1α activity and that in absence of TAp73, HIF1α is 
upregulated. In contrast, Np73 enhances HIF1α activity. In Paper III, we studied the 
regulation of HIF1α by ΔNp73 in more detail.  
In Paper II, we continued to explore how TAp73 regulates one of the pro-angiogenic 
chemokines found in Paper I. Here we reported that TAp73 represses tumor-induced 
production of macrophage chemotactic protein 1(MCP1/CCL2). We also confirmed similar 
negative correlation between TP73 and CCL2 in six different cancer datasets. Importantly, we 
showed that TAp73-driven CCL2 repression is mainly conferred by inhibiting NFκB-mediated 
activation of the CCL2 promoter. We also found that TAp73 KO tumors that had higher 
expression of CCL2, also harbored increased tumor infiltrated macrophages. In addition, these 
macrophages were found to be mostly M2-like tumor associated macrophages (TAMs). We 
also reported similar negative correlation of TP73 and M2-like TAMs marker CD206 
expression in human breast cancer and lung cancer. 
In Paper III, we continued the study following a lead from Paper I. Here, we demonstrated 
that ΔNp73 positively regulates HIF1α stability. In absence of ΔNp73, HIF1α is rapidly 
ubiquitinated and degraded via proteasomal machinery and this degradation is dependent on 
pVHL. Similar downregulation of HIF1α in absence of ΔNp73 was further confirmed in in vivo 
tumors. Additionally, we revealed that ΔNp73 downregulates members of the ECV complex, 
which results in increased HIF1α stability and accumulation. Here we showed a novel 
mechanism through which ΔNp73 can control HIF1α stability by regulating the ECV genes.  
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In Paper IV, we focused our study on deciphering the role of p73 in cancer drug resistance, 
which is a very important factor in deciding patient drug therapy. Since, ΔNp73 is known to be 
aberrantly expressed in variety of cancers and is involved in chemoresistance, we focused our 
study on this isoform. We reported that oncogenic ΔNp73 supports drug resistance via 
promoting expression of ABC transporters. Additionally, we showed that ΔNp73 
overexpression promotes expression of ABCB1 and ABCB5 gene. On the other hand, 
downregulation of ΔNp73 results in decreased expression of the same ABC transporters that 
leads to decreased drug efflux capacity by breast cancer cells. In line with this, similar 
regulation was also confirmed in melanoma patient samples. Together our data demonstrated 
ΔNp73’s positive role in drug resistance that could hold significance in cancer patient therapy. 
In Paper I and II, we found that p73 regulates several pro-angiogenic factors. Some of these 
factors are known to have function in metastasis. Hence, it would be interesting to study p73 
isoforms involvement in tumor metastasis. In contrary to our Paper I, there are existing 
contradictory reports about TAp73 promoting tumor angiogenesis, this may imply that c-
terminal splice variants i.e. α, β, γ, δ, ε, ζ and η are also needed to be considered for drawing 
conclusions about different p73 isoforms’s function. Since CCL2 is known to promote tumor 
angiogenesis and recruitment of TAMs in TAp73 KO tumors, it would be interesting to see if 
these events could be reversed upon blocking of CCL2 expression in-vivo. Additionally, 
macrophages are also known to produce CCL2, as such, it would be interesting to study 
whether the absence or presence of TAp73 within macrophages may have any effect on 
macrophage function in tumor development. In Paper I and III, we showed the regulation of 
HIF1α by p73 isoforms. Therefore, regulation of other HIF family members by p73 isoforms 
would be an interesting area for further investigation. Moreover, p73ΔEx2/3 isoform that acts 
like ΔNp73 should also be investigated for its effect in regulation of HIF1α stability and tumor 
angiogenesis. In Paper IV we deciphered the role of ΔNp73 in drug resistance and regulation 
of ABC transporters, similarly, the involvement of TAp73 in the regulation of ABC 
transporters could be an exciting area to consider for future direction. 
In conclusion, this thesis delineates a novel mechanism by which p73 isoforms can influence 
the tumor microenvironment through differential regulation of angiogenic factors and 
subsequent angiogenic events. Furthermore, we confirm the oncogenic role of ΔNp73 in 
supporting multi-drug resistance through regulation of ABC transporters. By providing further 
knowledge on how p73 can affect tumor development and resistance, we highlight the 
significance of p73 as an important target for the design of new cancer therapies. 
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